<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:23:00Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9590190" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9590190</identifier>
        <datestamp>2022-10-25</datestamp>
        <setSpec>biosexdiff</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Biol Sex Differ</journal-id>
              <journal-id journal-id-type="iso-abbrev">Biol Sex Differ</journal-id>
              <journal-title-group>
                <journal-title>Biology of Sex Differences</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2042-6410</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9590190</article-id>
              <article-id pub-id-type="pmcid">PMC9590190</article-id>
              <article-id pub-id-type="pmc-uid">9590190</article-id>
              <article-id pub-id-type="pmid">36274158</article-id>
              <article-id pub-id-type="publisher-id">472</article-id>
              <article-id pub-id-type="doi">10.1186/s13293-022-00472-w</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect of progesterone administration in male and female smokers on nicotine withdrawal and neural response to smoking cues: role of progesterone conversion to allopregnanolone</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0995-5060</contrib-id>
                  <name>
                    <surname>Novick</surname>
                    <given-names>Andrew M.</given-names>
                  </name>
                  <address>
                    <email>andrew.m.novick@cuanschutz.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Duffy</surname>
                    <given-names>Korrina A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Johnson</surname>
                    <given-names>Rachel L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sammel</surname>
                    <given-names>Mary D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cao</surname>
                    <given-names>Wen</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Strasser</surname>
                    <given-names>Andrew A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sofuoglu</surname>
                    <given-names>Mehmet</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kuzma</surname>
                    <given-names>Alexandra</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Loughead</surname>
                    <given-names>James</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morrow</surname>
                    <given-names>A. Leslie</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Epperson</surname>
                    <given-names>C. Neill</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.430503.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0703 675X</institution-id><institution>Department of Psychiatry, School of Medicine, </institution><institution>University of CO-Anschutz Medical Campus, </institution></institution-wrap>13001 E 17th Pl, Aurora, CO 80045 USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.430503.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0703 675X</institution-id><institution>Department of Biostatistics and Informatics, Colorado School of Public Health, </institution><institution>University of CO-Anschutz Medical Campus, </institution></institution-wrap>Aurora, CO 80045 USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>Department of Psychiatry, Perelman School of Medicine, </institution><institution>University of Pennsylvania, </institution></institution-wrap>Philadelphia, PA 19104 USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.47100.32</institution-id><institution-id institution-id-type="ISNI">0000000419368710</institution-id><institution>Department of Psychiatry, </institution><institution>Yale School of Medicine, Yale University, </institution></institution-wrap>New Haven, CT 06511 USA </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.59062.38</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7689</institution-id><institution>Larner College of Medicine, </institution><institution>University of Vermont, </institution></institution-wrap>Burlington, VM 05405 USA </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Departments of Psychiatry and Pharmacology and the Bowles Center for Alcohol Studies, </institution><institution>University of North Carolina School of Medicine, </institution></institution-wrap>Chapel Hill, NC 27514 USA </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.430503.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0703 675X</institution-id><institution>Department of Family Medicine, School of Medicine, </institution><institution>University of CO-Anschutz Medical Campus, </institution></institution-wrap>Aurora, CO 80045 USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>23</day>
                <month>10</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>23</day>
                <month>10</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <volume>13</volume>
              <elocation-id>60</elocation-id>
              <history>
                <date date-type="received">
                  <day>4</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>15</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2022</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Progesterone administration has therapeutic effects in tobacco use disorder (TUD), with females benefiting more than males. Conversion of progesterone to the neurosteroid allopregnanolone is hypothesized to partly underlie the therapeutic effects of progesterone; however, this has not been investigated clinically.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">Smokers (<italic>n</italic> = 18 males, <italic>n</italic> = 21 females) participated in a randomized, double-blind, placebo-controlled crossover study of 200 mg progesterone daily across 4 days of abstinence. The ratio of allopregnanolone:progesterone was analyzed in relationship to nicotine withdrawal, smoking urges, mood states, subjective nicotine effects, and neural response to smoking cues.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">Allopregnanolone:progesterone ratio interacted with sex to predict withdrawal symptoms (<italic>p</italic> = 0.047), such that females with higher allopregnanolone:progesterone ratios reported lower withdrawal severity (<italic>b</italic> = − 0.98 [− 1.95, − 0.01]; <italic>p</italic> = 0.048). In addition, allopregnanolone:progesterone ratio interacted with sex to predict confusion (<italic>p</italic> = 0.014) and fatigue (<italic>p</italic> = 0.034), such that females with higher allopregnanolone:progesterone ratios reported less confusion (<italic>b</italic> = − 0.45 [− 0.78, − 0.12]; <italic>p</italic> = 0.008) and marginally lower fatigue (<italic>b</italic> = − 0.50 [− 1.03, 0.02]; <italic>p</italic> = 0.062. Irrespective of sex, higher ratios of allopregnanolone:progesterone were associated with stronger “good effects” of nicotine (<italic>b</italic> = 8.39 [2.58, 14.20]); <italic>p</italic> = 0.005) and weaker “bad effects” of nicotine (<italic>b</italic> = − 7.13 [− 13.53, − 0.73]; <italic>p</italic> = 0.029).</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p id="Par4">Conversion of progesterone to allopregnanolone correlated with smoking-related outcomes in both sex-dependent and sex-independent ways. Sex-dependent effects suggest that conversion of progesterone to allopregnanolone may contribute to greater therapeutic benefits in females but not males with TUD.</p>
                  <p id="Par5"><italic>Trial registration</italic> Clinicaltrials.gov registration, retrospectively registered: NCT01954966; <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01954966">https://clinicaltrials.gov/ct2/show/NCT01954966</ext-link>\</p>
                </sec>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1186/s13293-022-00472-w.</p>
                </sec>
              </abstract>
              <abstract id="Abs2" abstract-type="highlights">
                <title>Highlights</title>
                <p id="Par6">
                  <list list-type="bullet">
                    <list-item>
                      <p id="Par7">Progesterone has sex-dependent effects on smoking measures in individuals with Tobacco Use Disorder.</p>
                    </list-item>
                    <list-item>
                      <p id="Par8">Higher conversion of progesterone to allopregnanolone (as indicated by the allopregnanolone:progesterone ratio) was associated with lower nicotine withdrawal in female but not male smokers during a brief abstinence.</p>
                    </list-item>
                    <list-item>
                      <p id="Par9">Higher conversion of progesterone to allopregnanolone was associated with lower ratings of confusion and marginally lower ratings of fatigue in female but not male smokers.</p>
                    </list-item>
                    <list-item>
                      <p id="Par10">Irrespective of sex, higher conversion of progesterone to allopregnanolone was associated with stronger “good effects” and weaker “bad effects” of nicotine during active smoking.</p>
                    </list-item>
                  </list>
                </p>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1186/s13293-022-00472-w.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Smoking</kwd>
                <kwd>Progesterone</kwd>
                <kwd>Allopregnanolone</kwd>
                <kwd>Sex-differences</kwd>
                <kwd>Neurosteroids</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id>
                      <institution>National Institute on Drug Abuse</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01DA036289</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Epperson</surname>
                      <given-names>C. Neill</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id>
                      <institution>National Institute on Aging</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>U54AG062319</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Novick</surname>
                      <given-names>Andrew M.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>Ludeman Center for Women's Health Research, University of Colorado</institution>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par11">Sex differences in substance use disorders (SUDs) are common and vary depending upon the substance in question. While prevalence for most SUDs may be more common among males [<xref ref-type="bibr" rid="CR1">1</xref>], tobacco use disorder (TUD) is particularly concerning for females because they become dependent more quickly after exposure [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], experience greater health consequences [<xref ref-type="bibr" rid="CR4">4</xref>], are less responsive to nicotine replacement therapy [<xref ref-type="bibr" rid="CR5">5</xref>], and are more likely to relapse after abstinence [<xref ref-type="bibr" rid="CR6">6</xref>]. While the physiologic underpinnings for these observed sex differences are unknown, growing evidence suggests that neuroactive steroids should be considered given that they act on the brain structures [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>] and neurotransmitters [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>] impacted by nicotine yet differ in level and cyclicity between males and females.</p>
              <p id="Par12">Progesterone (PROG) and its gamma-aminobutyric acid (GABA)-A receptor modulating metabolite, allopregnanolone (ALLO), have been implicated in the pathophysiology and treatment of TUD as well as sex differences in TUD [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. ALLO modulates processes relevant to TUD, including reward [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref>], mood [<xref ref-type="bibr" rid="CR16">16</xref>], anxiety [<xref ref-type="bibr" rid="CR16">16</xref>], and cognition [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Delta-subunit containing GABA-A receptors for ALLO are located in similar brain regions as nicotinic acetylcholine receptors [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>], suggesting ALLO’s capacity to influence nicotine’s effects. A recent study in male rats found that a positive allosteric modulator of delta-subunit containing GABA-A receptors in the amygdala blocked stress-induced enhancement of nicotine self-administration [<xref ref-type="bibr" rid="CR21">21</xref>]. Unlike the GABA-A receptor, there is a lack of evidence for a direct role of the PROG receptor in processes related to TUD; however, in vitro experiments demonstrate that PROG and ALLO both separately inhibit activity of nicotinic acetylcholine receptors [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p>
              <p id="Par13">A clinical rationale for the therapeutic effects of PROG and ALLO in TUD developed from studies of female smokers who demonstrated greater success at quitting during the luteal phase of the menstrual cycle when endogenous levels of PROG and ALLO are both high relative to the follicular phase [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Furthermore, women demonstrate lower activation of reward-related brain regions, specifically the putamen, when viewing smoking cues in the luteal versus follicular phase of the menstrual cycle [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
              <p id="Par14">Among smokers, PROG administration decreases cigarette cravings [<xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR30">30</xref>], decreases amount smoked [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], decreases the rewarding effects of nicotine [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], and increases time to relapse [<xref ref-type="bibr" rid="CR33">33</xref>]. Females may benefit from PROG administration more than males [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. In studies examining sex differences in response to PROG administration, females but not males showed improved cognitive function during acute smoking abstinence [<xref ref-type="bibr" rid="CR30">30</xref>] and increased time to smoking relapse [<xref ref-type="bibr" rid="CR33">33</xref>]. In line with these findings, we found that PROG administration relative to placebo increased withdrawal severity in males but not females [<xref ref-type="bibr" rid="CR34">34</xref>]. Similarly, studies in humans and rodents with cocaine dependence demonstrate a benefit of PROG administration in females but not males [<xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR38">38</xref>], but see [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
              <p id="Par15">Limited research suggests that the primary effect of PROG on TUD may be through its conversion to ALLO—but whether this applies to both males and females in humans remains unclear. In male mice, administration of PROG or ALLO decreases anxiety-like behavior during nicotine withdrawal, but the effect of PROG on anxiety-like behavior is blocked when conversion to ALLO is inhibited [<xref ref-type="bibr" rid="CR39">39</xref>], suggesting that PROG’s effects act through its conversion to ALLO. A study conducted on patients with cocaine use disorder found that high levels of ALLO following administration of 400 mg PROG (or placebo) was associated with improved mood and cognitive performance under stress as well as reduced cocaine cravings; however, sex differences were not investigated [<xref ref-type="bibr" rid="CR17">17</xref>]. Sex differences in GABA-A receptor density [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>] suggest that males and females with TUD might have differential responses to PROG depending on the extent to which it is converted to ALLO.</p>
              <p id="Par16">Teasing out the effect of PROG versus ALLO on smoking behavior in humans is complex yet important as PROG is easily administered and well-tolerated [<xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Given evidence that PROG conversion to ALLO is necessary to observe behavioral and neural effects relevant to its use as a potential treatment for some SUDs, we measured ALLO:PROG ratio at multiple timepoints in male and female smokers receiving PROG and placebo during brief abstinence in a double-blind, randomized crossover study. Then, we tested whether ALLO:PROG ratio interacted with sex to predict therapeutic benefits across a comprehensive set of smoking-related behavioral, psychological, and neural measures.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods and materials</title>
              <sec id="Sec3">
                <title>Participants</title>
                <p id="Par17">We utilized data collected in a double-blind, randomized, placebo-controlled crossover study [<xref ref-type="bibr" rid="CR34">34</xref>]. Briefly, non-treatment-seeking male and female daily smokers 18–50 years old without current psychiatric or major medical illnesses were recruited for the study. Participants smoked at least 10 cigarettes per day over the past year, with a score of at least three on the Fagerström Test for Nicotine Dependence (FTND), and have an expired carbon monoxide (CO) level of at least 11 ppm. A full list of inclusion/exclusion criteria can be found in Table <xref rid="Tab1" ref-type="table">1</xref>. Further information on study screening is provided in Additional file <xref rid="MOESM1" ref-type="media">1</xref>. Of 131 potential participants screened for the study, 81 were enrolled, 66 were randomized, and 52 completed both periods. Of the 66 randomized, the analyzed sample had 39 participants for whom neurosteroid data were available. The Supplemental Materials contain information on missing data and participant attrition (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S1).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria for study participation</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Inclusion criteria</td></tr><tr><td align="left">• Adults 18–50 years old</td></tr><tr><td align="left">• Daily smokers for ≥ 12 months who smoke ≥ 10 cigarettes/day</td></tr><tr><td align="left"><p>• Fagerström test for nicotine dependence ≥ 3</p><p>• CO levels ≥ 11</p></td></tr><tr><td align="left"><p>• Not currently seeking treatment for nicotine dependence</p><p>• Clear urine drug screen (marijuana permissible)</p></td></tr><tr><td align="left"><p>• Not currently pregnant (females only)</p><p>• Regular menstrual cycle (females only)</p></td></tr><tr><td align="left">Exclusion criteria</td></tr><tr><td align="left">• Current major medical illness</td></tr><tr><td align="left">• Lifetime history of psychotic disorder (DSM-IV)</td></tr><tr><td align="left">• Other Axis 1 psychiatric disorder within past year (DSM-IV)</td></tr><tr><td align="left">• Lifetime history of substance dependence disorder other than nicotine (DSM-IV)</td></tr><tr><td align="left">• History of substance use disorder other than nicotine within past 2 years (DSM-IV)</td></tr><tr><td align="left">• Heavy alcohol use within past year (&gt; 7 drinks/week or &gt; 3 drinks/occasion for females; &gt; 14 drinks/week or &gt; 4 drinks/occasion for males)</td></tr><tr><td align="left">• Current regular use of any tobacco products other than cigarettes</td></tr><tr><td align="left">• Current regular use of psychotropic medication</td></tr><tr><td align="left">• Contraindications to progesterone use (e.g., thrombophlebitis, stroke)</td></tr><tr><td align="left">• Known progesterone or peanut allergy (Prometrium<sup>®</sup> contains peanut oil)</td></tr><tr><td align="left"><p>• Left-handed (for consistency in neuroimaging)</p><p>Weighs ≥ 300 lbs. (contraindication for fMRI)</p></td></tr><tr><td align="left">• Metallic implants (contraindication for fMRI)</td></tr><tr><td align="left">• Claustrophobic (contraindication for fMRI)</td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="Sec4">
                <title>Study design</title>
                <p id="Par18">As described in Novick et al. [<xref ref-type="bibr" rid="CR34">34</xref>], participants received oral micronized PROG (200 mg daily of Prometrium<sup>®</sup>) or placebo over a 4-day abstinence period followed by a washout period and subsequent crossover to the other period (for an overview of the study procedure and design, see Fig. <xref rid="Fig1" ref-type="fig">1</xref>). On day 1, participants received no drug but completed a 2-h ad lib smoking session to measure baseline smoking behavior and subjective responses to nicotine. They continued smoking as usual following the session. On day 2, participants smoked their last cigarette prior to entering the testing facility, beginning the abstinence period. They underwent the baseline fMRI scan within 30 min of their last cigarette. After the baseline scan, they were administered 200 mg PROG or placebo, and then they underwent a second fMRI scan to measure acute effects 3 h later (acute treatment timepoint). On days 3 and 4, participants self-administered 200 mg progesterone or placebo. On day 5, participants self-administered their final dose of progesterone or placebo and underwent a third fMRI scan to measure chronic effects (chronic treatment timepoint). This was followed by a post-treatment 2-h ad lib smoking session. Before each fMRI scan, participants completed questionnaires to measure withdrawal symptoms, smoking urges, and mood states. Each fMRI measured neural activation while participants viewed smoking and neutral cues. After each fMRI scan, blood was drawn to measure circulating levels of neurosteroids (e.g., PROG and ALLO).<fig id="Fig1"><label>Fig. 1</label><caption><p>Crossover study design. Functional magnetic resonance imaging (fMRI) scans measured neural activation in response to smoking and neutral cues. Participants completed measures of withdrawal symptoms, smoking urges, and mood states before each brain scan. Blood draws measured levels of neurosteroids, such as progesterone and allopregnanolone, after each brain scan. Smoking sessions measured change in carbon monoxide (CO) levels, number of cigarettes smoked, inhalation volume for the first cigarette, total inhalation volume during the session, and subjective nicotine effects at baseline and after a 4-day abstinence</p></caption><graphic xlink:href="13293_2022_472_Fig1_HTML" id="MO1"/></fig></p>
                <p id="Par19">After completion of the first period, male participants had a 1- to 2-week washout period before crossover to the second period in which the above procedures were repeated. All menstruating female participants had a 1- to 3-month washout period before crossover. For females who were naturally cycling or were continuing to experience menstrual cycles while using a long-acting form of contraception (e.g., an intrauterine device), all study days took place within 7 days of self-reported menses onset (early follicular phase). Menstruating females taking oral contraceptive pills were scheduled during the contraceptive placebo pill days of their cycle. This ensured that progesterone was being administered in the context of low endogenous estradiol and progesterone to minimize interactions with exogenous progesterone, a commonly used approach in progesterone trials [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p>
              </sec>
              <sec id="Sec5">
                <title>Procedures</title>
                <sec id="Sec6">
                  <title>Progesterone administration</title>
                  <p id="Par20">Micronized PROG (Prometrium) 200 mg capsules were obtained from Catalent Pharma Solutions, St. Petersburg, FL. This compound is identical in chemical structure to endogenous PROG synthesized in the body [<xref ref-type="bibr" rid="CR42">42</xref>]. Similar placebo capsules were prepared by the Investigational Drug Service at the University of Pennsylvania. The 200 mg once daily dose is commonly used to prevent endometrial hyperplasia in postmenopausal women receiving estrogen replacement therapy [<xref ref-type="bibr" rid="CR42">42</xref>] and is effective in attenuating smoking cravings and positive effects of smoking in females after overnight abstinence [<xref ref-type="bibr" rid="CR29">29</xref>].</p>
                </sec>
                <sec id="Sec7">
                  <title>Contingency management</title>
                  <p id="Par21">Contingency management was used to reinforce abstinence with modest monetary payments [<xref ref-type="bibr" rid="CR43">43</xref>]. To assess compliance with the abstinence protocol, study staff measured the participant’s alveolar CO levels twice per day on days 3 and 4 and once on day 5. To be considered compliant, participants needed a CO level of less than 10 ppm [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] or, if greater, it had to be continually decreasing across days 3–5 [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Based on CO levels, 11 participants had at least one smoking slip for a total of 16 slips across timepoints—8 in the PROG period and 8 in the placebo period. However, we used an intention-to-treat analytic approach to be conservative in our treatment effect estimates and therefore did not exclude these participants.</p>
                </sec>
                <sec id="Sec8">
                  <title>Outcome measures</title>
                  <sec id="Sec9">
                    <title>Behavioral measures</title>
                    <p id="Par22">Participants completed a 2-h ad lib smoking session on days 2 and 5. Before and after each smoking session, expired CO levels were measured using the Vitalograph Breathco™ carbon monoxide monitor to gauge acute exposure to tobacco smoke [<xref ref-type="bibr" rid="CR46">46</xref>]. To assess inhalation volume for the first cigarette and total inhalation volume over the session, participants smoked through a plastic cigarette holder, fitted to the filter end of the cigarette, and connected to a smoking topography device (CreSS from Plowshare Technologies). The number of cigarettes smoked was also measured. After smoking, participants completed the Nicotine Effects Questionnaire (NEQ) to measure the subjective effects of nicotine (see Table <xref rid="Tab2" ref-type="table">2</xref> for further details).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Descriptions of self-report measures</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Measure</th><th align="left">Description</th></tr></thead><tbody><tr><td align="left">Nicotine Effects Questionnaire</td><td align="left">The NEQ is a validated 4-item scale in which participants were asked to rate the strength of nicotine, experience of a head rush, as well as the good and bad effects of nicotine on a 0–100 sliding scale [<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td align="left">Nicotine Withdrawal Symptom Checklist</td><td align="left">The NWSC (also known as the Minnesota Nicotine Withdrawal Scale) is a validated 8-item scale of withdrawal symptoms, such as irritability, anxiety, insomnia, and depression, rated on a 5-point scale [<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left">Questionnaire on Smoking Urges-Brief</td><td align="left">The QSU-Brief is a validated 10-item scale in which participants rate the extent to which they agree with statements related to smoking urges and cravings on a 7-point scale [<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left">Questionnaire on Smoking Urges</td><td align="left">The QSU is a longer, 32-item version of the QSU-Brief in which participants rate items on a 7-point scale [<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left">Profile of Mood States</td><td align="left">The POMS is a 65-item questionnaire that measures six mood states: tension–anxiety, depression–dejection, anger–hostility, confusion–bewilderment, fatigue, and vigor [<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr></tbody></table></table-wrap></p>
                  </sec>
                  <sec id="Sec10">
                    <title>Psychological measures</title>
                    <p id="Par23">Participants completed the following self-report measures: the Nicotine Withdrawal Symptom Checklist (NWSC, also known as the Minnesota Nicotine Withdrawal Scale), the Brief Questionnaire of Smoking Urges (QSU-Brief), the Questionnaire on Smoking Urges (QSU), and the Profile of Mood States (POMS) (see Table <xref rid="Tab2" ref-type="table">2</xref> for further details). The NWSC, QSU-Brief, and POMS were administered at the baseline, acute, and chronic treatment timepoints. The QSU was administered only at the chronic treatment timepoint.</p>
                  </sec>
                  <sec id="Sec11">
                    <title>Neural measures</title>
                    <p id="Par24">Neural activation in response to smoking cues was assessed with BOLD imaging using a validated task [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>] described previously [<xref ref-type="bibr" rid="CR34">34</xref>] in which participants viewed grayscale images of smoking and neutral cues. Smoking cues were images of people smoking cigarettes, holding cigarettes, and handling smoking-related items, such as lighters. Neutral cues were images matched for visual content (e.g., a person with a pen in their mouth). To ensure participant engagement, a target stimulus (picture of an animal) was presented infrequently, and participants were instructed to respond with a button press. The task consisted of 20 smoking, 20 neutral, and four target images, with each image presented for four seconds. During the interstimulus interval, a fixation point appeared on a grey screen for a variable length of time (between 6–14 s). Midway through the task, the fixation point appeared during a 24-s rest period. Stimuli class was pseudo-randomized with no more than two images of a given image type being presented consecutively. The total task duration was 10 min and 36 s. Functionally defined regions of interest (ROIs) were derived from whole-brain group analysis of the baseline session smoking cue minus neutral cue contrast using FLAME (FMRIB's Local Analysis of Mixed Effects) [<xref ref-type="bibr" rid="CR54">54</xref>] (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). ROI masks were created via voxel-wise correction at <italic>p</italic> = 0.05. Percent signal change was extracted from ROIs that met a threshold of 200 voxels for all 6 sessions and 3 contrasts (smoking, neutral, smoking minus neutral). Additional information on fMRI acquisition and processing can be found in Additional file <xref rid="MOESM1" ref-type="media">1</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><p><italic>Z</italic>-score map of functionally defined regions of interest (ROIs) for the contrast smoking cue minus neutral measured at the baseline session. ROI masks were created via voxel-wise correction at <italic>p</italic> = 0.05. Percent signal change was extracted from these ROIs for all 6 sessions for subsequent analysis. Specific details on ROIs, including voxels, coordinates, and specific <italic>z</italic>-score can be found in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S13</p></caption><graphic xlink:href="13293_2022_472_Fig2_HTML" id="MO2"/></fig></p>
                  </sec>
                </sec>
                <sec id="Sec12">
                  <title>Neurosteroid measures</title>
                  <p id="Par25">After each fMRI scan, a blood sample was taken to measure the following neurosteroids: PROG, ALLO, 3a,5b-THP, pregnenolone, 3a,5a-androsterone, 3a,5b-androsterone, 3a,5a-androstandiol, 3a,5b-androstandiol, 3a,5a-THDOC, and 3a,5b-THDOC. Neurosteroids were analyzed using gas chromatography–mass spectrometry, as described previously [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. See Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig S2 for a diagram of the PROG metabolic pathway depicting the neurosteroids that were measured.</p>
                </sec>
              </sec>
              <sec id="Sec13">
                <title>Statistical plan</title>
                <p id="Par26">To test whether individual differences in the conversion of PROG to its metabolite ALLO predicted our behavioral, psychological, and neural smoking measures, we calculated the ratio of ALLO to PROG (ALLO:PROG ratio) at three timepoints: baseline, the acute timepoint, and the chronic timepoint. Ratios were log-transformed to normalize their distribution. Because our previous paper reported on the results of our clinical trial [<xref ref-type="bibr" rid="CR34">34</xref>] and we were interested in the association between ALLO:PROG ratio in the blood and smoking-related psychological, behavioral, and neural outcomes, we collapsed data across the PROG and placebo periods to increase statistical power. For all analyses, we controlled for drug condition. Although the main the purpose of this manuscript was to investigate associations with ALLO:PROG ratio, we present analyses with PROG levels and ALLO levels separately in Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p>
                <p id="Par27">Given our prediction that sex would moderate the association between ALLO:PROG ratio and our outcomes, all models first tested for an interaction between sex and ALLO:PROG ratio. Then, if the Type III interaction <italic>p</italic>-value was not significant at the level <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\alpha$$\end{document}</tex-math><mml:math id="M2"><mml:mi>α</mml:mi></mml:math><inline-graphic xlink:href="13293_2022_472_Article_IEq1.gif"/></alternatives></inline-formula> = 0.05, we tested for main effects of sex and ALLO:PROG ratio within the same model. We conducted these analyses for each of our psychological, behavioral, and neural smoking measures, modeling repeated outcome measures using generalized estimating equations (GEEs).</p>
                <p id="Par28">Our models differed in time point structures because different outcomes were measured at different timepoints depending on clinical interest. Our models assessing psychological outcomes used three repeated measures (baseline, acute, and chronic) per period for NWSC, QSU-Brief, and POMS; however, the QSU was only measured at the chronic timepoint for each period. Our behavioral outcomes (change in CO levels, number of cigarettes smoked, inhalation volume for first cigarette, total inhalation volume during the session, and subjective nicotine effects) were assessed at the final smoking session for each period. Our models assessing neural outcomes used two repeated measures (acute minus baseline, chronic minus baseline) to measure change in neural activation from baseline for each period. Neural activation outcomes were calculated as the difference between neural activation in response to the smoking cues minus the neutral cues for each period. This was computed separately for all four regions of interest (ROIs) identified using whole brain analysis: the posterior cingulate cortex (PCC), anterior cingulate cortex (ACC), left lateral occipital cortex, and left middle temporal gyrus. To account for repeated measures, models included an exchangeable correlation structure and adjusted for time. All models adjusted for drug condition as well as randomization order to account for potential order effects due to the crossover design. Analyses were performed in SAS 9.4 (SAS Institute, Cary, NC).</p>
              </sec>
            </sec>
            <sec id="Sec14">
              <title>Results</title>
              <sec id="Sec15">
                <title>Participant demographics</title>
                <p id="Par29">Thirty-nine participants (age: M = 36.1; SD = 8.7) were randomized to condition order (either placebo first or PROG first). Male (<italic>n</italic> = 18) and female (<italic>n</italic> = 21) daily smokers were represented in similar numbers in the overall sample. See Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1 for additional demographic information on our sample.</p>
              </sec>
              <sec id="Sec16">
                <title>Levels of progesterone, allopregnanolone, and allopregnanolone-to-progesterone ratio</title>
                <p id="Par30">In Table <xref rid="Tab3" ref-type="table">3</xref>a–c, we summarize the blood levels of PROG and ALLO measured at baseline and after participants received acute and chronic doses of oral micronized PROG/placebo.<table-wrap id="Tab3"><label>Table 3</label><caption><p>a–c Raw data on blood levels of progesterone and allopregnanolone</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="4">Placebo</th><th align="left" colspan="3">Progesterone</th></tr><tr><th align="left" colspan="2"><italic>N</italic></th><th align="left">Mean (SD)</th><th align="left">Median<break/>[min, max]</th><th align="left"><italic>N</italic></th><th align="left">Mean (SD)</th><th align="left">Median<break/>[min, max]</th></tr></thead><tbody><tr><td align="left" colspan="8"><bold>Baseline</bold></td></tr><tr><td align="left" colspan="8"><bold>a. Progesterone (pg/mL)</bold></td></tr><tr><td align="left" colspan="2"> Males</td><td char="." align="char">15</td><td char="(" align="char">361.2 (120.3)</td><td char="[" align="char">347.0 [200, 580]</td><td char="." align="char">18</td><td char="(" align="char">362.3 (144.1)</td><td char="[" align="char">339.5 [175, 733]</td></tr><tr><td align="left"> Females</td><td char="." align="char" colspan="2">16</td><td char="(" align="char">837.1 (869.1)</td><td char="[" align="char">459.0 [109, 3070]</td><td char="." align="char">17</td><td char="(" align="char">932.3 (1457.4)</td><td char="[" align="char">405.0 [153, 6090]</td></tr><tr><td align="left" colspan="8"><italic>Acute</italic></td></tr><tr><td align="left">  Males</td><td char="." align="char" colspan="2">14</td><td char="(" align="char">311.1 (104.3)</td><td char="[" align="char">302.0 [200, 590]</td><td char="." align="char">17</td><td char="(" align="char">5264.1 (3317.8)</td><td char="[" align="char">4690.0 [900, 14030]</td></tr><tr><td align="left">  Females</td><td char="." align="char" colspan="2">15</td><td char="(" align="char">959.1 (1054.8)</td><td char="[" align="char">439.0 [149, 3520]</td><td char="." align="char">16</td><td char="(" align="char">10,369.1 (9925.7)</td><td char="[" align="char">8440.0 [305, 36500]</td></tr><tr><td align="left" colspan="8"><italic>Chronic</italic></td></tr><tr><td align="left">  Males</td><td char="." align="char" colspan="2">15</td><td char="(" align="char">285.9 (104.3)</td><td char="[" align="char">272.0 [198, 529]</td><td char="." align="char">17</td><td char="(" align="char">8199.4 (6521.2)</td><td char="[" align="char">5630.0 [1730, 20700]</td></tr><tr><td align="left">  Females</td><td char="." align="char" colspan="2">15</td><td char="(" align="char">1444.8 (2237.1)</td><td char="[" align="char">406.0 [132, 8230]</td><td char="." align="char">15</td><td char="(" align="char">10,732.0 (10,218.6)</td><td char="[" align="char">9730.0 [1540, 37360]</td></tr><tr><td align="left" colspan="8"><bold>b. Allopregnanolone (pg/mL)</bold></td></tr><tr><td align="left" colspan="8"><italic>Baseline</italic></td></tr><tr><td align="left">  Males</td><td char="." align="char" colspan="2">15</td><td char="(" align="char">54.4 (76.1)</td><td char="[" align="char">26.5 [3.0, 312.5]</td><td char="." align="char">18</td><td char="(" align="char">53.6 (75.2)</td><td char="[" align="char">31.2 [3.5, 286.2]</td></tr><tr><td align="left">  Females</td><td char="." align="char" colspan="2">14</td><td char="(" align="char">101.7 (58.6)</td><td char="[" align="char">94.8 [43.2, 250.6]</td><td char="." align="char">17</td><td char="(" align="char">122.3 (85.2)</td><td char="[" align="char">98.3 [10.7, 319.7]</td></tr><tr><td align="left" colspan="8"><italic>Acute</italic></td></tr><tr><td align="left">  Males</td><td char="." align="char" colspan="2">17</td><td char="(" align="char">70.1 (72.3)</td><td char="[" align="char">41.1 [9.4, 258.3]</td><td char="." align="char">19</td><td char="(" align="char">6893.4 (7036.8)</td><td char="[" align="char">4548.7 [951.2, 31,885.8]</td></tr><tr><td align="left">  Females</td><td char="." align="char" colspan="2">17</td><td char="(" align="char">104.2 (68.5)</td><td char="[" align="char">103.5 [22.1, 246.6]</td><td char="." align="char">15</td><td char="(" align="char">5430.5 (4632.8)</td><td char="[" align="char">3905.6 [115.0, 12,727.3]</td></tr><tr><td align="left" colspan="8"><italic>Chronic</italic></td></tr><tr><td align="left">  Males</td><td char="." align="char" colspan="2">17</td><td char="(" align="char">56.5 (60.7)</td><td char="[" align="char">36.3 [5.1, 252.5]</td><td char="." align="char">19</td><td char="(" align="char">6474.4 (4793.7)</td><td char="[" align="char">5600.4 [1007.4, 19,775.7]</td></tr><tr><td align="left">  Females</td><td char="." align="char" colspan="2">15</td><td char="(" align="char">142.2 (92.2)</td><td char="[" align="char">121.4 [32.0, 339.1]</td><td char="." align="char">16</td><td char="(" align="char">5551.5 (4477.0)</td><td char="[" align="char">5350.3 [213.2, 17,084.7]</td></tr><tr><td align="left" colspan="8"><bold>c. Log (allopregnanolone/progesterone)</bold></td></tr><tr><td align="left" colspan="8"><italic>Baseline</italic></td></tr><tr><td align="left">  Males</td><td char="." align="char" colspan="2">14</td><td char="(" align="char">− 2.3 (0.9)</td><td char="[" align="char">− 2.3 [− 4.4, − 0.6]</td><td char="." align="char">17</td><td char="(" align="char">− 2.5 (1.0)</td><td char="[" align="char">− 2.2 [− 4.6, − 0.8]</td></tr><tr><td align="left">  Females</td><td char="." align="char" colspan="2">13</td><td char="(" align="char">− 1.7 (1.1)</td><td char="[" align="char">− 1.4 [− 3.6, − 0.5]</td><td char="." align="char">17</td><td char="(" align="char">− 1.7 (0.9)</td><td char="[" align="char">− 1.8 [− 3.1, − 0.1]</td></tr><tr><td align="left" colspan="8"><italic>Acute</italic></td></tr><tr><td align="left">  Males</td><td char="." align="char" colspan="2">13</td><td char="(" align="char">− 1.9 (0.9)</td><td char="[" align="char">− 1.9 [− 3.5, 0.1]</td><td char="." align="char">17</td><td char="(" align="char">0.0 (0.5)</td><td char="[" align="char">0.1 [− 1.4, 0.8]</td></tr><tr><td align="left">  Females</td><td char="." align="char" colspan="2">14</td><td char="(" align="char">− 1.8 (1.1)</td><td char="[" align="char">− 1.5 [− 3.7, − 0.4]</td><td char="." align="char">13</td><td char="(" align="char">− 0.6 (0.7)</td><td char="[" align="char">− 0.8 [− 1.5, 0.8]</td></tr><tr><td align="left" colspan="8"><italic>Chronic</italic></td></tr><tr><td align="left">  Males</td><td char="." align="char" colspan="2">15</td><td char="(" align="char">− 1.9 (0.8)</td><td char="[" align="char">− 1.9 [− 3.7, − 0.2]</td><td char="." align="char">17</td><td char="(" align="char">− 0.1 (0.8)</td><td char="[" align="char">0.0 [− 1.5, 0.8]</td></tr><tr><td align="left">  Females</td><td char="." align="char" colspan="2">15</td><td char="(" align="char">− 1.7 (1.3)</td><td char="[" align="char">− 1.0 [− 4.2, − 0.2]</td><td char="." align="char">15</td><td char="(" align="char">− 0.8 (1.0)</td><td char="[" align="char">− 0.7 [− 3.3, 1.2]</td></tr></tbody></table><table-wrap-foot><p>Mean, standard deviation, median, and range of (a) progesterone, (b) allopregnanolone, and (c) the ratio of allopregnanolone:progesterone at baseline, the acute treatment timepoint, and the chronic treatment timepoint separated by drug (progesterone vs. placebo) and stratified by sex</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec17">
                <title>Psychological measures</title>
                <p id="Par31">Sex interacted with ALLO:PROG ratio to predict withdrawal severity (NWSC: difference in slopes: <italic>b</italic> = − 1.12 [− 2.01, − 0.22]; <italic>p</italic> = 0.047) but not smoking urges (QSU-Brief: <italic>p</italic> = 0.420; QSU: <italic>p</italic> = 0.179). For NWSC, the simple slope for females showed lower nicotine withdrawal symptoms with higher ratios of ALLO:PROG (<italic>b</italic> = − 0.98 [− 1.95, − 0.01]; <italic>p</italic> = 0.048; Fig. <xref rid="Fig3" ref-type="fig">3</xref>). For the mood state subscales (POMS), the interaction effect was significant for fatigue (difference in slopes: <italic>b</italic> = − 0.58 [− 1.08, − 0.08]; <italic>p</italic> = 0.034; Fig. <xref rid="Fig3" ref-type="fig">3</xref>) and for confusion–bewilderment (difference in slopes: <italic>b</italic> = − 0.55 [− 0.99, − 0.11]; <italic>p</italic> = 0.014; Fig. <xref rid="Fig3" ref-type="fig">3</xref>). The simple slope was significant for confusion–bewilderment for females such that higher ALLO:PROG ratio was associated with reduced confusion–bewilderment (<italic>b</italic> = − 0.45 [− 0.78, − 0.12]; <italic>p</italic> = 0.008; Fig. <xref rid="Fig3" ref-type="fig">3</xref>). For all interaction model results, see Table <xref rid="Tab4" ref-type="table">4</xref>. Given that the interaction effect and simple slopes by sex were not significant for QSU-Brief, QSU, and other five POMS subscales, we tested for main effects of ALLO:PROG ratio and sex. However, no significant main effects emerged for any of the measures (<italic>p</italic>s &gt; 0.05). For all main effect model results, see Table <xref rid="Tab5" ref-type="table">5</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><p>Significant interaction of allopregnanolone:progesterone ratio and sex on withdrawal symptoms and mood states. <bold>A</bold> Allopregnanolone:progesterone ratio and sex significantly interacted to predict nicotine withdrawal symptoms (<italic>p</italic> = 0.047) on the Nicotine Withdrawal Symptom Checklist. The simple slope for females was significant, such that having a higher ratio of allopregnanolone:progesterone was associated with lower withdrawal symptoms (<italic>p</italic> = 0.048). <bold>B</bold> Allopregnanolone:progesterone ratio significantly interacted with sex to predict fatigue on the Profile of Moods Scale (POMS) (<italic>p</italic> = 0.034). For females, a higher ratio of allopregnanolone:progesterone was marginally associated with lower reports of fatigue (<italic>p</italic> = 0.062). <bold>C</bold> Allopregnanolone:progesterone ratio significantly interacted with sex to predict confusion on the POMS. For females, higher ratios of allopregnanolone:progesterone were associated with lower reports of confusion (<italic>p</italic> = 0.008). For details see Table <xref rid="Tab3" ref-type="table">4</xref></p></caption><graphic xlink:href="13293_2022_472_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab4"><label>Table 4</label><caption><p>Interaction effect of allopregnanolone:progesterone ratio and sex on self-reported psychological measures</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Outcome</th><th align="left">Log (allo/prog) by sex interaction<break/><italic>p</italic> value</th><th align="left">Within females:<break/>Effect of log(allo/prog)<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">Within males:<break/>Effect of log(allo/prog)<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">Difference between slopes (95% CI)</th></tr></thead><tbody><tr><td align="left">QSU-Brief</td><td char="." align="char">0.420</td><td char="(" align="char">− 2.05 (− 5.36, 1.26)</td><td char="." align="char">0.225</td><td char="(" align="char">− 0.40 (− 2.92, 2.12)</td><td char="." align="char">0.756</td><td char="(" align="char">− 1.65 (− 5.46, 2.16)</td></tr><tr><td align="left">NWSC</td><td char="." align="char">0.047<sup>b</sup></td><td char="(" align="char">− 0.98 (− 1.95, − 0.01)</td><td char="." align="char">0.048<sup>b</sup></td><td char="(" align="char">0.13 (− 0.39, 0.67)</td><td char="." align="char">0.612</td><td char="(" align="char">− 1.12 (− 2.01, − 0.22)</td></tr><tr><td align="left">QSU<sup>a</sup></td><td char="." align="char">0.179</td><td char="(" align="char">− 1.07 (− 9.16, 7.03)</td><td char="." align="char">0.796</td><td char="(" align="char">8.81 (− 4.52, 22.15)</td><td char="." align="char">0.195</td><td char="(" align="char">− 9.88 (− 24.29, 4.53)</td></tr><tr><td align="left">POMS: tension–anxiety</td><td char="." align="char">0.201</td><td char="(" align="char">− 0.38 (− 1.13, 0.38)</td><td char="." align="char">0.330</td><td char="(" align="char">0.20 (− 0.29, 0.68)</td><td char="." align="char">0.428</td><td char="(" align="char">− 0.57 (− 1.37, 0.22)</td></tr><tr><td align="left">POMS: depression–dejection</td><td char="." align="char">0.937</td><td char="(" align="char">0.09 (− 0.57, 0.75)</td><td char="." align="char">0.785</td><td char="(" align="char">0.12 (− 0.12, 0.36)</td><td char="." align="char">0.328</td><td char="(" align="char">− 0.03 (− 0.66, 0.61)</td></tr><tr><td align="left">POMS: anger–hostility</td><td char="." align="char">0.118</td><td char="(" align="char">− 0.52 (− 1.24, 0.20)</td><td char="." align="char">0.115</td><td char="(" align="char">0.05 (− 0.40, 0.51)</td><td char="." align="char">0.815</td><td char="(" align="char">− 0.57 (− 1.17, 0.02)</td></tr><tr><td align="left">POMS: fatigue</td><td char="." align="char">0.034<sup>b</sup></td><td char="(" align="char">− 0.50 (− 1.03, 0.02)</td><td char="." align="char">0.062</td><td char="(" align="char">0.08 (− 0.37, 0.53)</td><td char="." align="char">0.724</td><td char="(" align="char">− 0.58 (− 1.08, − 0.08)</td></tr><tr><td align="left">POMS: vigor</td><td char="." align="char">0.262</td><td char="(" align="char">1.05 (− 0.16, 2.26)</td><td char="." align="char">0.089</td><td char="(" align="char">0.19 (− 0.69, 1.06)</td><td char="." align="char">0.675</td><td char="(" align="char">0.87 (− 0.55, 2.28)</td></tr><tr><td align="left">POMS: confusion–bewilderment</td><td char="." align="char">0.014<sup>b</sup></td><td char="(" align="char">− 0.45 (− 0.78, − 0.12)</td><td char="." align="char">0.008<sup>b</sup></td><td char="(" align="char">0.10 (− 0.11, 0.31)</td><td char="." align="char">0.352</td><td char="(" align="char">− 0.55 (− 0.99, − 0.11)</td></tr></tbody></table><table-wrap-foot><p>For each outcome, the interaction effect and simple slopes by sex are depicted</p><p><italic>QSU-Brief</italic> Brief Questionnaire on Smoking Urges, <italic>NWSC</italic> Nicotine Withdrawal Symptom Checklist, <italic>QSU</italic> Tiffany Questionnaire of Smoking Urges, <italic>POMS</italic> Profile of Mood States</p><p><sup>a</sup>Only at final scan (‘chronic’ visit); no repeated measures</p><p><sup>b</sup>Statistical significance at level <italic>p</italic> &lt; 0.05</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Main effects of allopregnanolone:progesterone ratio and sex on self-reported psychological measures that did not show a significant interaction effect in Table <xref rid="Tab3" ref-type="table">4</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Outcome</th><th align="left">Effect of log(allo/prog)</th><th align="left"><italic>p</italic> value</th><th align="left">Effect of sex gender [ref: female]<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">QSU-Brief</td><td char="(" align="char">− 0.94 (− 3.19, 1.31)</td><td char="." align="char">0.412</td><td char="(" align="char">− 0.38 (− 7.17, 6.40)</td><td char="." align="char">0.912</td></tr><tr><td align="left">QSU<sup>a</sup></td><td char="(" align="char">4.38 (− 5.30, 14.06)</td><td char="." align="char">0.375</td><td char="(" align="char">− 17.42 (− 38.37, 3.54)</td><td char="." align="char">0.103</td></tr><tr><td align="left">POMS: tension–anxiety</td><td char="(" align="char">0.00 (− 0.46, 0.47)</td><td char="." align="char">0.987</td><td char="(" align="char">0.44 (− 0.92, 1.80)</td><td char="." align="char">0.526</td></tr><tr><td align="left">POMS: depression–dejection</td><td char="(" align="char">0.11 (− 0.20, 0.42)</td><td char="." align="char">0.490</td><td char="(" align="char">− 0.26 (− 1.51, 0.98)</td><td char="." align="char">0.681</td></tr><tr><td align="left">POMS: anger–hostility</td><td char="(" align="char">− 0.14 (− 0.65, 0.38)</td><td char="." align="char">0.606</td><td char="(" align="char">− 0.29 (− 1.67, 1.08)</td><td char="." align="char">0.676</td></tr><tr><td align="left">POMS: vigor</td><td char="(" align="char">0.44 (− 0.32, 1.20)</td><td char="." align="char">0.258</td><td char="(" align="char">2.13 (− 1.55, 5.82)</td><td char="." align="char">0.257</td></tr></tbody></table><table-wrap-foot><p><italic>QSU-Brief</italic> Brief Questionnaire on Smoking Urges, <italic>NWSC</italic> Nicotine Withdrawal Symptom Checklist, <italic>QSU</italic> Tiffany Questionnaire of Smoking Urges, <italic>POMS</italic> Profile of Mood States</p><p><sup>a</sup>Only at final scan (‘chronic’ visit); no repeated measures</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec18">
                <title>Behavioral measures during a laboratory-based smoking session</title>
                <p id="Par32">Sex did not interact with ALLO:PROG ratio to predict any of the smoking behaviors measured at the end of the 4-day abstinence period: change in CO levels from before and after the smoking session (<italic>p</italic> = 0.237), number of cigarettes smoked (<italic>p</italic> = 0.148), inhalation volume for first cigarette (<italic>p</italic> = 0.803), total inhalation volume during the session (<italic>p</italic> = 0.256), and subjective effects from smoking (all four items on NEQ; <italic>p</italic> &gt; 0.05). However, the simple slope for males was significant for two items on the NEQ. For males, higher ratios of ALLO:PROG were associated with higher perceived good effects (<italic>b</italic> = 9.36 [1.72, 17.00]; <italic>p</italic> = 0.016) and lower perceived bad effects (<italic>b</italic> = − 11.34 [− 20.50, − 2.18]; <italic>p</italic> = 0.015). For all interaction model results, see Table <xref rid="Tab6" ref-type="table">6</xref>. Given the lack of a significant interaction effect, we tested for main effects of ALLO:PROG ratio and sex. The only two significant findings were that higher ratios of ALLO:PROG were associated with stronger “good” (<italic>b</italic> = 8.39 [2.59, 14.20]; <italic>p</italic> = 0.005) and weaker “bad” (<italic>b</italic> = − 7.13 [− 13.53, − 0.73]; <italic>p</italic> = 0.029) effects from smoking, which was driven by males as indicated above. For all main effect model results, see Table <xref rid="Tab7" ref-type="table">7</xref>.<table-wrap id="Tab6"><label>Table 6</label><caption><p>Interaction effect allopregnanolone:progesterone ratio and sex on final smoking session measures</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Outcome at final smoking session</th><th align="left">Log(allo/prog) by sex interaction<break/><italic>p</italic> value</th><th align="left">Within females:<break/>Effect of log(allo/prog)<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">Within males:<break/>Effect of log(allo/prog)<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">Difference (95% CI) between slopes</th></tr></thead><tbody><tr><td align="left">CO (post–pre)</td><td char="." align="char">0.237</td><td char="(" align="char">− 1.81 (− 4.12, 0.51)</td><td char="." align="char">0.127</td><td char="(" align="char">0.55 (− 2.15, 3.26)</td><td char="." align="char">0.689</td><td char="(" align="char">− 2.36 (− 5.92, 1.20)</td></tr><tr><td align="left">Number of cigarettes</td><td char="." align="char">0.148</td><td char="(" align="char">− 0.13 (− 0.42, 0.17)</td><td char="." align="char">0.401</td><td char="(" align="char">0.20 (− 0.20, 0.61)</td><td char="." align="char">0.327</td><td char="(" align="char">− 0.33 (− 0.72, 0.06)</td></tr><tr><td align="left">Volume smoked (1st cigarette)</td><td char="." align="char">0.803</td><td char="(" align="char">− 77.9 (− 222.6, 88.9)</td><td char="." align="char">0.360</td><td char="(" align="char">− 49.5 (− 286.7, 187.7)</td><td char="." align="char">0.683</td><td char="(" align="char">− 28.3 (− 251.0, 194.3)</td></tr><tr><td align="left">Total volume smoked</td><td char="." align="char">0.256</td><td char="(" align="char">193.1 (− 410.6, 796.8)</td><td char="." align="char">0.531</td><td char="(" align="char">548.2 (− 120.4, 1216.7)</td><td char="." align="char">0.108</td><td char="(" align="char">− 355.0 (− 889.9, 179.8)</td></tr><tr><td align="left">NEQ1 (feel strength of nicotine)</td><td char="." align="char">0.983</td><td char="(" align="char">2.54 (− 3.22, 8.31)</td><td char="." align="char">0.387</td><td char="(" align="char">2.46 (− 3.86, 8.79)</td><td char="." align="char">0.445</td><td char="(" align="char">0.08 (− 7.18, 7.34)</td></tr><tr><td align="left">NEQ2 (feel “good” effects of nicotine)</td><td char="." align="char">0.519</td><td char="(" align="char">6.45 (− 0.71, 13.60)</td><td char="." align="char">0.077</td><td char="(" align="char">9.36 (1.72, 17.00)</td><td char="." align="char">0.016<sup>a</sup></td><td char="(" align="char">− 2.91 (− 11.94, 6.12)</td></tr><tr><td align="left">NEQ3 (feel “bad” effects of nicotine)</td><td char="." align="char">0.140</td><td char="(" align="char">− 2.99 (− 9.99, 4.01)</td><td char="." align="char">0.402</td><td char="(" align="char">− 11.34 (− 20.50, − 2.18)</td><td char="." align="char">0.015<sup>a</sup></td><td char="(" align="char">8.35 (− 1.53, 18.23)</td></tr><tr><td align="left">NEQ4 (head rush)</td><td char="." align="char">0.589</td><td char="(" align="char">− 8.62 (− 18.82, 1.57)</td><td char="." align="char">0.097</td><td char="(" align="char">− 4.49 (− 16.22, 7.24)</td><td char="." align="char">0.453</td><td char="(" align="char">− 4.14 (− 19.20, 10.93)</td></tr></tbody></table><table-wrap-foot><p>For each outcome, the interaction effect and simple slopes by sex are depicted</p><p><italic>NEQ</italic> Nicotine Effects Questionnaire</p><p><sup>a</sup> Statistical significance at level <italic>p</italic> &lt; 0.05</p></table-wrap-foot></table-wrap><table-wrap id="Tab7"><label>Table 7</label><caption><p>Main effects of allopregnanolone:progesterone ratio and sex on smoking session measures that did not show a significant interaction effect in Table <xref rid="Tab5" ref-type="table">6</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Outcome at final smoking session</th><th align="left">Effect of log(allo/prog)<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">Effect of sex<break/>[ref: female]<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">CO (post–pre)</td><td char="(" align="char">− 0.65 (− 2.58, 1.27)</td><td char="." align="char">0.504</td><td char="(" align="char">1.18 (− 3.40, 5.75)</td><td char="." align="char">0.614</td></tr><tr><td align="left">Number of cigarettes</td><td char="(" align="char">0.04 (− 0.29, 0.37)</td><td char="." align="char">0.821</td><td char="(" align="char">− 0.15 (− 0.87, 0.57)</td><td char="." align="char">0.684</td></tr><tr><td align="left">Volume smoked (1st cigarette)</td><td char="(" align="char">− 65.4 (− 232.8, 102.1)</td><td char="." align="char">0.444</td><td char="(" align="char">− 129.1 (− 489.6, 231.5)</td><td char="." align="char">0.483</td></tr><tr><td align="left">Total volume smoked</td><td char="(" align="char">369.9 (− 229.0, 968.8)</td><td char="." align="char">0.226</td><td char="(" align="char">− 1030.0 (− 2671.0, 611.1)</td><td char="." align="char">0.219</td></tr><tr><td align="left">NEQ1 (feel strength of nicotine)</td><td char="(" align="char">2.81 (− 2.17, 7.79)</td><td char="." align="char">0.269</td><td char="(" align="char">− 0.24 (− 17.84, 17.35)</td><td char="." align="char">0.979</td></tr><tr><td align="left">NEQ2 (feel “good” effects of nicotine)</td><td char="(" align="char">8.39 (2.58, 14.20)</td><td char="." align="char">0.005<sup>a</sup></td><td char="(" align="char">− 12.03 (− 28.98, 4.93)</td><td char="." align="char">0.165</td></tr><tr><td align="left">NEQ3 (feel “bad” effects of nicotine)</td><td char="(" align="char">− 7.13 (− 13.53, − 0.73)</td><td char="." align="char">0.029<sup>a</sup></td><td char="(" align="char">14.80 (− 1.05, 30.64)</td><td char="." align="char">0.067</td></tr><tr><td align="left">NEQ4 (head rush)</td><td char="(" align="char">− 5.41 (− 14.59, 1.77)</td><td char="." align="char">0.125</td><td char="(" align="char">16.33 (− 4.43, 37.09)</td><td char="." align="char">0.123</td></tr></tbody></table><table-wrap-foot><p><italic>NEQ</italic> Nicotine Effects Questionnaire</p><p><sup>a</sup>Statistical significance at level <italic>p</italic> &lt; 0.05</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec19">
                <title>Neural activation when viewing smoking cues</title>
                <p id="Par33">No interactions of ALLO:PROG ratio and sex emerged for any of the ROIs tested (see Table <xref rid="Tab8" ref-type="table">8</xref>). Given the lack of significant interactions, we tested for main effects of ALLO:PROG ratio and sex. For all main effect model results, see Table <xref rid="Tab9" ref-type="table">9</xref>.<table-wrap id="Tab8"><label>Table 8</label><caption><p>Interaction of allopregnanolone:progesterone ratio and sex on neural activation when viewing smoking cues (minus neutral cues)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Outcome</th><th align="left">Log(allo/prog) by sex interaction<break/><italic>p</italic> value</th><th align="left">Within females:<break/>Effect of log(allo/prog)<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">Within males:<break/>Effect of log(allo/prog)<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">Difference in slopes (95% CI)</th></tr></thead><tbody><tr><td align="left">PCC</td><td char="." align="char">0.181</td><td char="(" align="char">0.03 (− 0.07, 0.14)</td><td char="." align="char">0.504</td><td char="(" align="char">− 0.05 (− 0.13, 0.03)</td><td char="." align="char">0.253</td><td char="(" align="char">0.08 (− 0.03, 0.20)</td></tr><tr><td align="left">ACC</td><td char="." align="char">0.406</td><td char="(" align="char">− 0.01 (− 0.09, 0.08)</td><td char="." align="char">0.904</td><td char="(" align="char">− 0.04 (− 0.10, 0.01)</td><td char="." align="char">0.133</td><td char="(" align="char">0.04 (− 0.05, 0.13)</td></tr><tr><td align="left">Lateral occipital cortex (left)</td><td char="." align="char">0.201</td><td char="(" align="char">0.00 (− 0.07, 0.08)</td><td char="." align="char">0.900</td><td char="(" align="char">− 0.05 (− 0.12, 0.02)</td><td char="." align="char">0.172</td><td char="(" align="char">0.05 (− 0.03, 0.13)</td></tr><tr><td align="left">Middle temporal gyrus (left)</td><td char="." align="char">0.213</td><td char="(" align="char">0.04 (− 0.06, 0.13)</td><td char="." align="char">0.467</td><td char="(" align="char">− 0.02 (− 0.09, 0.05)</td><td char="." align="char">0.517</td><td char="(" align="char">0.06 (− 0.03, 0.15)</td></tr></tbody></table><table-wrap-foot><p>For each region of interest, the interaction effect and simple slopes by sex are depicted</p><p><italic>PCC</italic> posterior cingulate cortex, <italic>ACC</italic> anterior cingulate cortex</p></table-wrap-foot></table-wrap><table-wrap id="Tab9"><label>Table 9</label><caption><p>Main effects allopregnanolone:progesterone ratio and sex on neural activation when viewing smoking cues (minus neutral cues) in regions that did not show a significant interaction effect in Table <xref rid="Tab7" ref-type="table">8</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Outcome</th><th align="left">Effect of log(allo/prog)</th><th align="left"><italic>p</italic> value</th><th align="left">Effect of sex<break/>[ref: female]<break/>(95% CI)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">PCC</td><td char="(" align="char">− 0.02 (− 0.10, 0.06)</td><td char="." align="char">0.564</td><td char="(" align="char">0.14 (0.00, 0.28)</td><td char="." align="char">0.048<sup>a</sup></td></tr><tr><td align="left">ACC</td><td char="(" align="char">− 0.03 (− 0.09, 0.02)</td><td char="." align="char">0.243</td><td char="(" align="char">0.07 (− 0.06, 0.20)</td><td char="." align="char">0.292</td></tr><tr><td align="left">Lateral occipital cortex (left)</td><td char="(" align="char">− 0.03 (− 0.10, 0.03)</td><td char="." align="char">0.318</td><td char="(" align="char">0.09 (− 0.02, 0.21)</td><td char="." align="char">0.122</td></tr><tr><td align="left">Middle temporal gyrus (left)</td><td char="(" align="char">− 0.01 (− 0.07, 0.06)</td><td char="." align="char">0.837</td><td char="(" align="char">0.09 (− 0.03, 0.21)</td><td char="." align="char">0.160</td></tr></tbody></table><table-wrap-foot><p><italic>PCC</italic> posterior cingulate cortex, <italic>ACC</italic> anterior cingulate cortex</p><p><sup>a</sup>Statistical significance at level <italic>p</italic> &lt; 0.05</p></table-wrap-foot></table-wrap></p>
              </sec>
            </sec>
            <sec id="Sec20">
              <title>Discussion</title>
              <p id="Par34">To our knowledge, this is the first study to assess the extent to which conversion to ALLO following PROG or placebo treatment is associated with smoking-related behavioral, psychological, and neural outcomes. Significant sex differences emerged in how ALLO:PROG ratios correlated with various smoking-related outcomes. In females, but not males, greater ALLO:PROG ratios were associated with lower nicotine withdrawal, lower confusion, and marginally lower fatigue. Our findings add to previous studies demonstrating differential effects of PROG on smoking outcomes depending on sex [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] and suggest that the conversion of PROG to ALLO produces different effects in males and females. More specifically, some of our findings suggest that females but not males benefit from higher levels of ALLO relative to PROG levels and that conversion of PROG to ALLO may underlie aspects of its therapeutic effects in substance use disorders in females. Interestingly, despite these correlations, we did not see these correlations with ALLO levels alone (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). This may indicate differential and perhaps opposing effects of ALLO and PROG. For example, ALLO has GABAergic effects while PROG does not, and PROG has genomic actions whereas ALLO does not [<xref ref-type="bibr" rid="CR57">57</xref>].</p>
              <p id="Par35">Previously, we reported that, relative to placebo, PROG treatment resulted in increased withdrawal symptoms in males undergoing brief abstinence but had no effect in females [<xref ref-type="bibr" rid="CR34">34</xref>]. The present results reveal that a higher ALLO:PROG ratio in females is associated with decreased withdrawal symptoms, raising the possibility that PROG treatment in females might be even more effective in relieving withdrawal symptoms if ALLO conversion could be increased. Furthermore, although ALLO:PROG ratio did not show a significant relationship to withdrawal symptoms in males, its simple slope was in the opposite direction to that in females, suggesting that increases in conversion of ALLO to PROG could lack a therapeutic benefit in males on nicotine withdrawal and may explain why in our previously published clinical trial analyses males showed worse withdrawal symptoms during abstinence with PROG treatment compared with placebo [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
              <p id="Par36">Higher ALLO:PROG ratios predicted less confusion in females but not males. Although subjective reports of confusion differ from objective measures of cognitive performance, another study found that exogenous PROG improved performance on the Stroop task in female but not male abstinent smokers [<xref ref-type="bibr" rid="CR30">30</xref>]. Attentional difficulties are commonly encountered during abstinence from smoking and alleviation of such cognitive difficulties has been proposed as a treatment strategy for TUD [<xref ref-type="bibr" rid="CR58">58</xref>–<xref ref-type="bibr" rid="CR60">60</xref>]. An additional sex by ALLO:PROG ratio interaction emerged for reported fatigue, with females reporting marginally less fatigue with greater ALLO:PROG ratio. This has relevance for TUD given that higher levels of exhaustion are associated with greater tendency for relapse [<xref ref-type="bibr" rid="CR61">61</xref>].</p>
              <p id="Par37">Little research exists to explain why higher ALLO:PROG ratios were associated with more beneficial effects in female versus male smokers. Two studies suggest that female smokers may have a GABAergic deficit that PROG to ALLO conversion could alleviate [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Specifically, female chronic smokers have lower levels of ALLO in the blood compared to non-smokers [<xref ref-type="bibr" rid="CR62">62</xref>], suggesting less basal GABAergic neurosteroid activity. In a separate study that evaluated both males and females, female smokers demonstrated lower brain levels of GABA compared to non-smoking peers, while male smokers did not demonstrate differences in GABA levels compared to non-smoking males [<xref ref-type="bibr" rid="CR63">63</xref>]. It is also possible that differing steroid metabolism and elimination between sexes could contribute to more therapeutic benefits in females associated with ALLO:PROG ratios. Although there is evidence of similar pharmacokinetics for PROG in males and females [<xref ref-type="bibr" rid="CR42">42</xref>], if significant sex differences existed for the half-life of ALLO, that might influence the therapeutic impact of PROG conversion to ALLO. However, to evaluate this definitively, it would be necessary to conduct pharmacokinetic studies of both PROG and ALLO and confirm that similar processes were occurring in the brain.</p>
              <p id="Par38">The results did not reveal any correlations between neural activation to smoking cues and the ALLO:PROG ratio in either males in females. This was in line with our previous results that PROG administration (without taking into account hormone levels) lacked significant influence on neural activation to smoking cues compared to placebo. It is important to note that steroid levels were measured in serum and not the brain, which are not always correlated [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. However, the fact that PROG administration generally increases ALLO:PROG ratio in serum suggests that this likely occurs in the brain as well, given the presence of similar enzymes in the brain and periphery [<xref ref-type="bibr" rid="CR66">66</xref>]. Nevertheless, smoking-related measures in the current study, including the fMRI measures, might be more tightly linked to brain levels of ALLO or ALLO:PROG ratios since GABA-A receptors are localized to brain regions associated with nicotine action [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p>
              <p id="Par39">For outcomes with no interaction of sex by ALLO:PROG ratio, several main effects of ALLO:PROG ratio emerged. Higher ALLO:PROG ratios were associated with more a pleasant smoking experience during the smoking session based on the NEQ. Specifically, higher ALLO:PROG ratios were associated with stronger “good effects” and weaker “bad effects” of smoking. Interestingly, PROG levels demonstrate an opposite effect, at least in females, with higher PROG levels associated with weaker “good effects” of smoking (Additional file <xref rid="MOESM1" ref-type="media">1</xref>), suggestive of ALLO and PROG having opposite effects on the smoking experience. The mechanism by which greater ALLO conversion could impact subjective drug effects remains unclear. In male rats, ALLO has been found to increase baseline and morphine-induced dopamine release in the nucleus accumbens [<xref ref-type="bibr" rid="CR67">67</xref>]. However, a more recent rodent study found that ALLO decreases (rather than increases) electrically evoked burst dopamine release to a greater extent in males versus females, which would be expected to decrease the reported good effects of nicotine [<xref ref-type="bibr" rid="CR68">68</xref>]. Thus, additional research in humans is needed to understand the mechanisms by which ALLO may impact the subjective effects of nicotine. Nonetheless, these results suggest that the influence of ALLO conversion may not be universally therapeutic.</p>
            </sec>
            <sec id="Sec21">
              <title>Perspectives and significance</title>
              <p id="Par40">The present study provides insight into previously observed sex differences in the therapeutic potential of PROG for treatment of TUD—namely, that females seemed to benefit more than males. The differential relationships between ALLO:PROG ratio and smoking-related outcomes in males and females suggest sex differences in how the brain responds to PROG depending on the extent of metabolic conversion to ALLO. In females, having a higher ALLO:PROG ratio was associated with lower withdrawal symptom severity, lower ratings of confusion, and marginally lower ratings of fatigue during a brief smoking abstinence. Although conversion of PROG to ALLO was associated with more positive subjective effects of smoking for both sexes, in females uncoverted PROG may have an opposite effect and decrease positive subjective effects. To understand the mechanisms driving our effects, future studies should compare the efficacy of PROG administration, direct ALLO administration, and enzyme inhibitors (to prevent conversion to ALLO and other neurosteroid metabolites) on smoking-related measures. In addition, it will be important to determine differences between PROG and various progestins used for contraception on smoking-related measures as the latter are not metabolized into allopregnanolone [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Information</title>
              <sec id="Sec22">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="13293_2022_472_MOESM1_ESM.docx">
                      <caption>
                        <p><bold>Additional file 1: Fig S1.</bold> CONSORT diagram. <bold>Fig S2.</bold> Progesterone metabolic pathway diagram. The circled neurosteroids were measured in blood samples. <bold>Table S1.</bold> Participant characteristics. <bold>Table S2.</bold> Interaction effect of progesterone levels and sex on self-reported psychological measures. <bold>Table S3.</bold> Main effects of progesterone levels and sex on self-reported psychological measures (for non-significant interactions from Table S2). <bold>Table S3.</bold> Interaction effect of progesterone levels and sex on smoking session measures. <bold>Table S4.</bold> Main effects of progesterone levels and sex on smoking session measures (for non-significant interactions from Table S3). <bold>Table S5.</bold> Interaction of progesterone levels and sex on neural activation when viewing smoking cues minus neutral cues. <bold>Table S6.</bold> Main effects progesterone and sex on neural activation when viewing smoking cues minus neutral cues (for non-significant interactions from Table S5). <bold>Table S7.</bold> Interaction effect of allopregnanolone levels and sex on self-reported psychological measures. <bold>Table S8.</bold> Main effects of allopregnanolone levels and sex on self-reported psychological measures (for non-significant interactions from Table S7). <bold>Table S9.</bold> Interaction effect of allopregnanolone levels and sex on smoking session measures. <bold>Table S10.</bold> Main effects of allopregnanolone levels and sex on smoking session measures (for non-significant interactions from Table S9). <bold>Table S11.</bold> Interaction of allopregnanolone levels and sex on neural activation when viewing smoking cues minus neutral cues. <bold>Table S12.</bold> Main effects allopregnanolone levels and sex on neural activation when viewing smoking cues minus neutral cues (for non-significant interactions from Table S11S). <bold>Table S13.</bold> Functionally defined regions of interest (ROIs) included in analysis, originally identified for the smoking minus neutral contrast at the baseline session with a threshold of 200 voxels and voxel-wise correction of <italic>p</italic> = 0.05.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher's Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>AMN: original draft preparation and review and editing of manuscript. KAD: review and editing of manuscript; visualization of data. RLJ: data curation; formal analysis; visualization of data. MDS: conceptualization; formal analysis, review and editing of manuscript. WC: investigation; formal analysis; visualization of data. MS: methodology; review and editing of manuscript. AAS: methodology; review and editing of manuscript. AK: investigation. JL: methodology; formal analysis; review and editing of manuscript. AL: methodology; investigation; resources; formal analysis and review and editing of manuscript. CNE: conceptualization; methodology; supervision; funding acquisition; and review and editing of manuscript. All authors read and approved the final manuscript.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This work was supported by the National Institutes of Health grants R01DA036289 (CNE) and U54AG062319 (AMN; PI Wendy Kohrt) as well as funding from the Ludeman Center for Women's Health Research, University of Colorado (AMN). Fig <xref rid="Fig1" ref-type="fig">1</xref> was designed with biorender.com.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Availability of data and materials</title>
              <p>The data underlying this article are available through Open Science Framework, at <ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.17605/OSF.IO/V7CN8">https://dx.doi.org/10.17605/OSF.IO/V7CN8</ext-link>.</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1">
                <title>Ethics approval and consent to participate</title>
                <p id="Par41">All participants provided either verbal or written informed consent for all study procedures. The University of Pennsylvania’s institutional review board approved all research activities.</p>
              </notes>
              <notes id="FPar2">
                <title>Consent for publication</title>
                <p id="Par42">Not applicable.</p>
              </notes>
              <notes id="FPar3" notes-type="COI-statement">
                <title>Competing interests</title>
                <p id="Par43">CNE has served on advisory boards for Asarina Pharma and Sage Therapeutics and has been a consultant and received grant support from Sage Therapeutics. ALM is a consultant for Sage Therapeutics and Pure Tech health. ALM holds a provisional patent on the anti-inflammatory actions of allopregnanolone and related steroids on toll-like receptor pathways in the immune system and brain.</p>
                <p id="Par44">AMN, KAD, RLJ, MDS, WC, MS, AAS, AK, and JL reported no biomedical interested or potential conflicts of interest.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>Center for Behavioral Health Statistics and Quality</collab>
                  </person-group>
                  <source>2020 National survey on drug use and health: detailed tables</source>
                  <year>2020</year>
                  <publisher-loc>Rockville</publisher-loc>
                  <publisher-name>Substance Abuse and Mental Health Services Administration</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>DiFranza</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Savageau</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Rigotti</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Fletcher</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Ockene</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>McNeill</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Development of symptoms of tobacco dependence in youths: 30 month follow up data from the DANDY study</article-title>
                  <source>Tob Control</source>
                  <year>2002</year>
                  <volume>11</volume>
                  <issue>3</issue>
                  <fpage>228</fpage>
                  <lpage>235</lpage>
                  <?supplied-pmid 12198274?>
                  <pub-id pub-id-type="pmid">12198274</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thorner</surname>
                      <given-names>ED</given-names>
                    </name>
                    <name>
                      <surname>Jaszyna-Gasior</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Epstein</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Moolchan</surname>
                      <given-names>ET</given-names>
                    </name>
                  </person-group>
                  <article-title>Progression to daily smoking: is there a gender difference among cessation treatment seekers?</article-title>
                  <source>Subst Use Misuse</source>
                  <year>2007</year>
                  <volume>42</volume>
                  <issue>5</issue>
                  <fpage>829</fpage>
                  <lpage>835</lpage>
                  <?supplied-pmid 17613947?>
                  <pub-id pub-id-type="pmid">17613947</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health</collab>
                  </person-group>
                  <source>The health consequences of smoking—50 years of progress: a report of the surgeon general (Reports of the Surgeon General)</source>
                  <year>2014</year>
                  <publisher-loc>Atlanta</publisher-loc>
                  <publisher-name>Centers for Disease Control and Prevention (US)</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Perkins</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Sex differences in long-term smoking cessation rates due to nicotine patch</article-title>
                  <source>Nicotine Tob Res</source>
                  <year>2008</year>
                  <volume>10</volume>
                  <issue>7</issue>
                  <fpage>1245</fpage>
                  <lpage>1251</lpage>
                  <?supplied-pmid 18629735?>
                  <pub-id pub-id-type="pmid">18629735</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>PH</given-names>
                    </name>
                    <name>
                      <surname>Bessette</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Weinberger</surname>
                      <given-names>AH</given-names>
                    </name>
                    <name>
                      <surname>Sheffer</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>McKee</surname>
                      <given-names>SA</given-names>
                    </name>
                  </person-group>
                  <article-title>Sex/gender differences in smoking cessation: a review</article-title>
                  <source>Prev Med</source>
                  <year>2016</year>
                  <volume>92</volume>
                  <fpage>135</fpage>
                  <lpage>140</lpage>
                  <?supplied-pmid 27471021?>
                  <pub-id pub-id-type="pmid">27471021</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Markou</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Neurobiology of nicotine dependence</article-title>
                  <source>Philos Trans R Soc Lond B Biol Sci</source>
                  <year>2008</year>
                  <volume>363</volume>
                  <issue>1507</issue>
                  <fpage>3159</fpage>
                  <lpage>3168</lpage>
                  <?supplied-pmid 18640919?>
                  <pub-id pub-id-type="pmid">18640919</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Willing</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Wagner</surname>
                      <given-names>CK</given-names>
                    </name>
                  </person-group>
                  <article-title>Progesterone receptor expression in the developing mesocortical dopamine pathway: importance for complex cognitive behavior in adulthood</article-title>
                  <source>Neuroendocrinology</source>
                  <year>2016</year>
                  <volume>103</volume>
                  <issue>3–4</issue>
                  <fpage>207</fpage>
                  <lpage>222</lpage>
                  <?supplied-pmid 26065828?>
                  <pub-id pub-id-type="pmid">26065828</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vashchinkina</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Manner</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Vekovischeva</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>den Hollander</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Uusi-Oukari</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Aitta-aho</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neurosteroid agonist at GABA a receptor induces persistent neuroplasticity in VTA dopamine neurons</article-title>
                  <source>Neuropsychopharmacology</source>
                  <year>2014</year>
                  <volume>39</volume>
                  <issue>3</issue>
                  <fpage>727</fpage>
                  <lpage>737</lpage>
                  <?supplied-pmid 24077066?>
                  <pub-id pub-id-type="pmid">24077066</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bali</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jaggi</surname>
                      <given-names>AS</given-names>
                    </name>
                  </person-group>
                  <article-title>Multifunctional aspects of allopregnanolone in stress and related disorders</article-title>
                  <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
                  <year>2014</year>
                  <volume>48</volume>
                  <fpage>64</fpage>
                  <lpage>78</lpage>
                  <?supplied-pmid 24044974?>
                  <pub-id pub-id-type="pmid">24044974</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Anker</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of progestins in the behavioral effects of cocaine and other drugs of abuse: human and animal research</article-title>
                  <source>Neurosci Biobehav Rev</source>
                  <year>2010</year>
                  <volume>35</volume>
                  <issue>2</issue>
                  <fpage>315</fpage>
                  <lpage>333</lpage>
                  <?supplied-pmid 20398693?>
                  <pub-id pub-id-type="pmid">20398693</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lynch</surname>
                      <given-names>WJ</given-names>
                    </name>
                    <name>
                      <surname>Sofuoglu</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of progesterone in nicotine addiction: evidence from initiation to relapse</article-title>
                  <source>Exp Clin Psychopharmacol</source>
                  <year>2010</year>
                  <volume>18</volume>
                  <issue>6</issue>
                  <fpage>451</fpage>
                  <lpage>461</lpage>
                  <?supplied-pmid 21186920?>
                  <pub-id pub-id-type="pmid">21186920</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frye</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Rhodes</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <article-title>Infusions of 3α,5α-THP to the VTA enhance exploratory, anti-anxiety, social, and sexual behavior and increase levels of 3α,5α-THP in midbrain, hippocampus, diencephalon, and cortex of female rats</article-title>
                  <source>Behav Brain Res</source>
                  <year>2008</year>
                  <volume>187</volume>
                  <issue>1</issue>
                  <fpage>88</fpage>
                  <lpage>99</lpage>
                  <?supplied-pmid 17919744?>
                  <pub-id pub-id-type="pmid">17919744</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fish</surname>
                      <given-names>EW</given-names>
                    </name>
                    <name>
                      <surname>Whitman</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>DiBerto</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Morrow</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Malanga</surname>
                      <given-names>CJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of the neuroactive steroid allopregnanolone on intracranial self-stimulation in C57BL/6J mice</article-title>
                  <source>Psychopharmacology</source>
                  <year>2014</year>
                  <volume>231</volume>
                  <issue>17</issue>
                  <fpage>3415</fpage>
                  <lpage>3423</lpage>
                  <?supplied-pmid 24810108?>
                  <pub-id pub-id-type="pmid">24810108</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Peart</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Andrade</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Logan</surname>
                      <given-names>CN</given-names>
                    </name>
                    <name>
                      <surname>Knackstedt</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Murray</surname>
                      <given-names>JE</given-names>
                    </name>
                  </person-group>
                  <article-title>Regulation of cocaine-related behaviours by estrogen and progesterone</article-title>
                  <source>Neurosci Biobehav Rev</source>
                  <year>2022</year>
                  <volume>135</volume>
                  <fpage>104584</fpage>
                  <?supplied-pmid 35189163?>
                  <pub-id pub-id-type="pmid">35189163</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schüle</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Nothdurfter</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Rupprecht</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of allopregnanolone in depression and anxiety</article-title>
                  <source>Prog Neurobiol</source>
                  <year>2014</year>
                  <volume>113</volume>
                  <fpage>79</fpage>
                  <lpage>87</lpage>
                  <?supplied-pmid 24215796?>
                  <pub-id pub-id-type="pmid">24215796</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Milivojevic</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Fox</surname>
                      <given-names>HC</given-names>
                    </name>
                    <name>
                      <surname>Sofuoglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Covault</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sinha</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of progesterone stimulated allopregnanolone on craving and stress response in cocaine dependent men and women</article-title>
                  <source>Psychoneuroendocrinology</source>
                  <year>2016</year>
                  <volume>65</volume>
                  <fpage>44</fpage>
                  <lpage>53</lpage>
                  <?supplied-pmid 26716877?>
                  <pub-id pub-id-type="pmid">26716877</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parks</surname>
                      <given-names>EE</given-names>
                    </name>
                    <name>
                      <surname>Logan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Yeganeh</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Farley</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Owen</surname>
                      <given-names>DB</given-names>
                    </name>
                    <name>
                      <surname>Sonntag</surname>
                      <given-names>WE</given-names>
                    </name>
                  </person-group>
                  <article-title>Interleukin 6 reduces allopregnanolone synthesis in the brain and contributes to age-related cognitive decline in mice</article-title>
                  <source>J Lipid Res</source>
                  <year>2020</year>
                  <volume>61</volume>
                  <issue>10</issue>
                  <fpage>1308</fpage>
                  <lpage>1319</lpage>
                  <?supplied-pmid 32669383?>
                  <pub-id pub-id-type="pmid">32669383</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Picciotto</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Caldarone</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>King</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Zachariou</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>Nicotinic receptors in the brain: links between molecular biology and behavior</article-title>
                  <source>Neuropsychopharmacology</source>
                  <year>2000</year>
                  <volume>22</volume>
                  <issue>5</issue>
                  <fpage>451</fpage>
                  <lpage>465</lpage>
                  <?supplied-pmid 10731620?>
                  <pub-id pub-id-type="pmid">10731620</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schwarzer</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Berresheim</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Pirker</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Wieselthaler</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fuchs</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sieghart</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Distribution of the major ?-aminobutyric acid A receptor subunits in the basal ganglia and associated limbic brain areas of the adult rat</article-title>
                  <source>J Comp Neurol</source>
                  <year>2001</year>
                  <volume>433</volume>
                  <issue>4</issue>
                  <fpage>526</fpage>
                  <lpage>549</lpage>
                  <?supplied-pmid 11304716?>
                  <pub-id pub-id-type="pmid">11304716</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sharp</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Jiang</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Simeone</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Scholze</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Allosteric modulation of GABAA receptors in rat basolateral amygdala blocks stress-enhanced reacquisition of nicotine self-administration</article-title>
                  <source>ACS Pharmacol Transl Sci</source>
                  <year>2020</year>
                  <volume>3</volume>
                  <issue>6</issue>
                  <fpage>1158</fpage>
                  <lpage>1164</lpage>
                  <?supplied-pmid 33344894?>
                  <pub-id pub-id-type="pmid">33344894</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Paradiso</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sabey</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Evers</surname>
                      <given-names>AS</given-names>
                    </name>
                    <name>
                      <surname>Zorumski</surname>
                      <given-names>CF</given-names>
                    </name>
                    <name>
                      <surname>Covey</surname>
                      <given-names>DF</given-names>
                    </name>
                    <name>
                      <surname>Steinbach</surname>
                      <given-names>JH</given-names>
                    </name>
                  </person-group>
                  <article-title>Steroid Inhibition of rat neuronal nicotinic α4β2 receptors expressed in HEK 293 cells</article-title>
                  <source>Mol Pharmacol</source>
                  <year>2000</year>
                  <volume>58</volume>
                  <issue>2</issue>
                  <fpage>341</fpage>
                  <lpage>351</lpage>
                  <?supplied-pmid 10908302?>
                  <pub-id pub-id-type="pmid">10908302</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bullock</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Clark</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Grady</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>SF</given-names>
                    </name>
                    <name>
                      <surname>Slobe</surname>
                      <given-names>BS</given-names>
                    </name>
                    <name>
                      <surname>Marks</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes</article-title>
                  <source>J Neurochem</source>
                  <year>2002</year>
                  <volume>68</volume>
                  <issue>6</issue>
                  <fpage>2412</fpage>
                  <lpage>2423</lpage>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Allen</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Bade</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Center</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Finstad</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hatsukami</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Menstrual phase effects on smoking relapse</article-title>
                  <source>Addiction</source>
                  <year>2008</year>
                  <volume>103</volume>
                  <issue>5</issue>
                  <fpage>809</fpage>
                  <lpage>821</lpage>
                  <?supplied-pmid 18412759?>
                  <pub-id pub-id-type="pmid">18412759</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mazure</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Toll</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>McKee</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>O’Malley</surname>
                      <given-names>SS</given-names>
                    </name>
                  </person-group>
                  <article-title>Menstrual cycle phase at quit date and smoking abstinence at six weeks in an open label trial of bupropion</article-title>
                  <source>Drug Alcohol Depend</source>
                  <year>2011</year>
                  <volume>114</volume>
                  <issue>1</issue>
                  <fpage>68</fpage>
                  <lpage>72</lpage>
                  <?supplied-pmid 20832955?>
                  <pub-id pub-id-type="pmid">20832955</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Franklin</surname>
                      <given-names>TR</given-names>
                    </name>
                    <name>
                      <surname>Jagannathan</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Ketcherside</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Spilka</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Wetherill</surname>
                      <given-names>RR</given-names>
                    </name>
                  </person-group>
                  <article-title>Menstrual cycle phase modulates responses to smoking cues in the putamen: preliminary evidence for a novel target</article-title>
                  <source>Drug Alcohol Depend</source>
                  <year>2019</year>
                  <volume>198</volume>
                  <fpage>100</fpage>
                  <lpage>104</lpage>
                  <?supplied-pmid 30901743?>
                  <pub-id pub-id-type="pmid">30901743</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Allen</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Tosun</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Carlson</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Allen</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Postpartum changes in mood and smoking-related symptomatology: an ecological momentary assessment investigation</article-title>
                  <source>Nicotine Tob Res</source>
                  <year>2018</year>
                  <volume>20</volume>
                  <issue>6</issue>
                  <fpage>681</fpage>
                  <lpage>689</lpage>
                  <?supplied-pmid 28575412?>
                  <pub-id pub-id-type="pmid">28575412</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Forray</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gilstad-Hayden</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Suppies</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bogen</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Sofuoglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Yonkers</surname>
                      <given-names>KA</given-names>
                    </name>
                  </person-group>
                  <article-title>Progesterone for smoking relapse prevention following delivery: a pilot, randomized, double-blind study</article-title>
                  <source>Psychoneuroendocrinology</source>
                  <year>2017</year>
                  <volume>86</volume>
                  <fpage>96</fpage>
                  <lpage>103</lpage>
                  <?supplied-pmid 28926762?>
                  <pub-id pub-id-type="pmid">28926762</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sofuoglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Babb</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Hatsukami</surname>
                      <given-names>DK</given-names>
                    </name>
                  </person-group>
                  <article-title>Progesterone treatment during the early follicular phase of the menstrual cycle: effects on smoking behavior in women</article-title>
                  <source>Pharmacol Biochem Behav</source>
                  <year>2001</year>
                  <volume>69</volume>
                  <issue>1–2</issue>
                  <fpage>299</fpage>
                  <lpage>304</lpage>
                  <?supplied-pmid 11420098?>
                  <pub-id pub-id-type="pmid">11420098</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sofuoglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mouratidis</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mooney</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers</article-title>
                  <source>Psychoneuroendocrinology</source>
                  <year>2011</year>
                  <volume>36</volume>
                  <issue>1</issue>
                  <fpage>123</fpage>
                  <lpage>132</lpage>
                  <?supplied-pmid 20675057?>
                  <pub-id pub-id-type="pmid">20675057</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Allen</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Petersen</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Harrison</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Nair</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Allen</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of exogenous progesterone administration on smoking topography</article-title>
                  <source>Addict Behav</source>
                  <year>2021</year>
                  <volume>112</volume>
                  <fpage>106570</fpage>
                  <?supplied-pmid 32763623?>
                  <pub-id pub-id-type="pmid">32763623</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sofuoglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Mooney</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokers</article-title>
                  <source>Hum Psychopharmacol Clin Exp</source>
                  <year>2009</year>
                  <volume>24</volume>
                  <issue>7</issue>
                  <fpage>559</fpage>
                  <lpage>564</lpage>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tosun</surname>
                      <given-names>NL</given-names>
                    </name>
                    <name>
                      <surname>Fieberg</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Eberly</surname>
                      <given-names>LE</given-names>
                    </name>
                    <name>
                      <surname>Harrison</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Tipp</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Allen</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Exogenous progesterone for smoking cessation in men and women: a pilot double-blind, placebo-controlled randomized clinical trial</article-title>
                  <source>Addiction</source>
                  <year>2019</year>
                  <volume>114</volume>
                  <issue>10</issue>
                  <fpage>1800</fpage>
                  <lpage>1813</lpage>
                  <?supplied-pmid 31059177?>
                  <pub-id pub-id-type="pmid">31059177</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Novick</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Duffy</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Sammel</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Cao</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Strasser</surname>
                      <given-names>AA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Progesterone increases nicotine withdrawal and anxiety in male but not female smokers during brief abstinence</article-title>
                  <source>Nicotine Tob Res</source>
                  <year>2022</year>
                  <pub-id pub-id-type="doi">10.1093/ntr/ntac146</pub-id>
                  <?supplied-pmid 35713950?>
                  <pub-id pub-id-type="pmid">35713950</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Anker</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Holtz</surname>
                      <given-names>NA</given-names>
                    </name>
                    <name>
                      <surname>Zlebnik</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of allopregnanolone on the reinstatement of cocaine-seeking behavior in male and female rats</article-title>
                  <source>Psychopharmacology</source>
                  <year>2009</year>
                  <volume>203</volume>
                  <issue>1</issue>
                  <fpage>63</fpage>
                  <lpage>72</lpage>
                  <?supplied-pmid 18998113?>
                  <pub-id pub-id-type="pmid">18998113</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Anker</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <article-title>Sex differences in the effects of allopregnanolone on yohimbine-induced reinstatement of cocaine seeking in rats</article-title>
                  <source>Drug Alcohol Depend</source>
                  <year>2010</year>
                  <volume>107</volume>
                  <issue>2</issue>
                  <fpage>264</fpage>
                  <lpage>267</lpage>
                  <?supplied-pmid 20005642?>
                  <pub-id pub-id-type="pmid">20005642</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Evans</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Foltin</surname>
                      <given-names>RW</given-names>
                    </name>
                  </person-group>
                  <article-title>Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men</article-title>
                  <source>Neuropsychopharmacology</source>
                  <year>2006</year>
                  <volume>31</volume>
                  <issue>3</issue>
                  <fpage>659</fpage>
                  <lpage>674</lpage>
                  <?supplied-pmid 16160708?>
                  <pub-id pub-id-type="pmid">16160708</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sofuoglu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Poling</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Gonsai</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Oliveto</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kosten</surname>
                      <given-names>TR</given-names>
                    </name>
                  </person-group>
                  <article-title>Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study</article-title>
                  <source>Exp Clin Psychopharmacol</source>
                  <year>2007</year>
                  <volume>15</volume>
                  <issue>5</issue>
                  <fpage>453</fpage>
                  <lpage>460</lpage>
                  <?supplied-pmid 17924779?>
                  <pub-id pub-id-type="pmid">17924779</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thakre</surname>
                      <given-names>PP</given-names>
                    </name>
                    <name>
                      <surname>Tundulwar</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Chopde</surname>
                      <given-names>CT</given-names>
                    </name>
                    <name>
                      <surname>Ugale</surname>
                      <given-names>RR</given-names>
                    </name>
                  </person-group>
                  <article-title>Neurosteroid allopregnanolone attenuates development of nicotine withdrawal behavior in mice</article-title>
                  <source>Neurosci Lett</source>
                  <year>2013</year>
                  <volume>541</volume>
                  <fpage>144</fpage>
                  <lpage>149</lpage>
                  <?supplied-pmid 23485740?>
                  <pub-id pub-id-type="pmid">23485740</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Reddy</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Matthew Carver</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Clossen</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>X</given-names>
                    </name>
                  </person-group>
                  <article-title>Extrasynaptic GABA-A receptor-mediated sex differences in the antiseizure activity of neurosteroids in status epilepticus and complex partial seizures</article-title>
                  <source>Epilepsia</source>
                  <year>2019</year>
                  <volume>60</volume>
                  <issue>4</issue>
                  <fpage>730</fpage>
                  <lpage>743</lpage>
                  <?supplied-pmid 30895610?>
                  <pub-id pub-id-type="pmid">30895610</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Samba</surname>
                      <given-names>RD</given-names>
                    </name>
                  </person-group>
                  <article-title>Sex differences in the anticonvulsant activity of neurosteroids</article-title>
                  <source>J Neurosci Res</source>
                  <year>2017</year>
                  <volume>95</volume>
                  <issue>1–2</issue>
                  <fpage>661</fpage>
                  <lpage>670</lpage>
                  <pub-id pub-id-type="pmid">27870400</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <mixed-citation publication-type="other">PROMETRIUM- progesterone capsule [package insert]. Langhorne: Virtus Pharmaceuticals; 2021. <ext-link ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a451784e-f6a0-414a-8409-3407f1d1d086">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a451784e-f6a0-414a-8409-3407f1d1d086</ext-link>. Accessed 5 Jun 2021.</mixed-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ledgerwood</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Contingency management for smoking cessation: where do we go from here?</article-title>
                  <source>CDAR</source>
                  <year>2008</year>
                  <volume>1</volume>
                  <issue>3</issue>
                  <fpage>340</fpage>
                  <lpage>349</lpage>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>SRNT Subcommittee on Biochemical Verification</collab>
                  </person-group>
                  <article-title>Biochemical verification of tobacco use and cessation</article-title>
                  <source>Nicotine Tob Res</source>
                  <year>2002</year>
                  <volume>4</volume>
                  <issue>2</issue>
                  <fpage>149</fpage>
                  <lpage>159</lpage>
                  <pub-id pub-id-type="pmid">12028847</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kralikova</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kozak</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Rasmussen</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Gustavsson</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Le Houezec</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler</article-title>
                  <source>BMC Public Health</source>
                  <year>2009</year>
                  <volume>9</volume>
                  <issue>1</issue>
                  <fpage>433</fpage>
                  <?supplied-pmid 19943947?>
                  <pub-id pub-id-type="pmid">19943947</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Burling</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Stitzer</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Bigelow</surname>
                      <given-names>GE</given-names>
                    </name>
                    <name>
                      <surname>Mead</surname>
                      <given-names>AM</given-names>
                    </name>
                  </person-group>
                  <article-title>Smoking topography and carbon monoxide levels in smokers</article-title>
                  <source>Addict Behav</source>
                  <year>1985</year>
                  <volume>10</volume>
                  <issue>3</issue>
                  <fpage>319</fpage>
                  <lpage>323</lpage>
                  <?supplied-pmid 4083109?>
                  <pub-id pub-id-type="pmid">4083109</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <mixed-citation publication-type="other">Niaura R, Hitsman B, Abrams D, Rohsenow D, Monti P. Validation and replication of the Nicotine Effects Questionnaire. In: Nicotine &amp; Tobacco Research. Taylor &amp; Francis Ltd; 2003. pp 788.</mixed-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cappelleri</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Bushmakin</surname>
                      <given-names>AG</given-names>
                    </name>
                    <name>
                      <surname>Baker</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Merikle</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Olufade</surname>
                      <given-names>AO</given-names>
                    </name>
                    <name>
                      <surname>Gilbert</surname>
                      <given-names>DG</given-names>
                    </name>
                  </person-group>
                  <article-title>Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale</article-title>
                  <source>Curr Med Res Opin</source>
                  <year>2005</year>
                  <volume>21</volume>
                  <issue>5</issue>
                  <fpage>749</fpage>
                  <lpage>760</lpage>
                  <?supplied-pmid 15969874?>
                  <pub-id pub-id-type="pmid">15969874</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cox</surname>
                      <given-names>LS</given-names>
                    </name>
                    <name>
                      <surname>Tiffany</surname>
                      <given-names>ST</given-names>
                    </name>
                    <name>
                      <surname>Christen</surname>
                      <given-names>AG</given-names>
                    </name>
                  </person-group>
                  <article-title>Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings</article-title>
                  <source>Nicotine Tobacco Res</source>
                  <year>2001</year>
                  <volume>3</volume>
                  <issue>1</issue>
                  <fpage>7</fpage>
                  <lpage>16</lpage>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tiffany</surname>
                      <given-names>ST</given-names>
                    </name>
                    <name>
                      <surname>Drobes</surname>
                      <given-names>DJ</given-names>
                    </name>
                  </person-group>
                  <article-title>The development and initial validation of a questionnaire on smoking urges</article-title>
                  <source>Br J Addict</source>
                  <year>1991</year>
                  <volume>86</volume>
                  <issue>11</issue>
                  <fpage>1467</fpage>
                  <lpage>1476</lpage>
                  <?supplied-pmid 1777741?>
                  <pub-id pub-id-type="pmid">1777741</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McNair</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Lorr</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Droppleman</surname>
                      <given-names>LF</given-names>
                    </name>
                    <collab>Educational and Industrial Testing Service</collab>
                  </person-group>
                  <source>Profile of mood states</source>
                  <year>1971</year>
                  <publisher-loc>San Diego</publisher-loc>
                  <publisher-name>Educational and Industrial Testing Service</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dumais</surname>
                      <given-names>KM</given-names>
                    </name>
                    <name>
                      <surname>Franklin</surname>
                      <given-names>TR</given-names>
                    </name>
                    <name>
                      <surname>Jagannathan</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Hager</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Gawrysiak</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Betts</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Multi-site exploration of sex differences in brain reactivity to smoking cues: consensus across sites and methodologies</article-title>
                  <source>Drug Alcohol Depend</source>
                  <year>2017</year>
                  <volume>178</volume>
                  <fpage>469</fpage>
                  <lpage>476</lpage>
                  <?supplied-pmid 28711813?>
                  <pub-id pub-id-type="pmid">28711813</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Janes</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Farmer</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Peechatka</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Frederick</surname>
                      <given-names>BdB</given-names>
                    </name>
                    <name>
                      <surname>Lukas</surname>
                      <given-names>SE</given-names>
                    </name>
                  </person-group>
                  <article-title>Insula-dorsal anterior cingulate cortex coupling is associated with enhanced brain reactivity to smoking cues</article-title>
                  <source>Neuropsychopharmacology</source>
                  <year>2015</year>
                  <volume>40</volume>
                  <issue>7</issue>
                  <fpage>1561</fpage>
                  <lpage>1568</lpage>
                  <?supplied-pmid 25567427?>
                  <pub-id pub-id-type="pmid">25567427</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Woolrich</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Behrens</surname>
                      <given-names>TEJ</given-names>
                    </name>
                    <name>
                      <surname>Beckmann</surname>
                      <given-names>CF</given-names>
                    </name>
                    <name>
                      <surname>Jenkinson</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Multilevel linear modelling for FMRI group analysis using Bayesian inference</article-title>
                  <source>Neuroimage</source>
                  <year>2004</year>
                  <volume>21</volume>
                  <issue>4</issue>
                  <fpage>1732</fpage>
                  <lpage>1747</lpage>
                  <?supplied-pmid 15050594?>
                  <pub-id pub-id-type="pmid">15050594</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Girdler</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Lindgren</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Porcu</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Rubinow</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Morrow</surname>
                      <given-names>AL</given-names>
                    </name>
                  </person-group>
                  <article-title>A history of depression in women is associated with an altered GABAergic neuroactive steroid profile</article-title>
                  <source>Psychoneuroendocrinology</source>
                  <year>2012</year>
                  <volume>37</volume>
                  <issue>4</issue>
                  <fpage>543</fpage>
                  <lpage>553</lpage>
                  <?supplied-pmid 21890277?>
                  <pub-id pub-id-type="pmid">21890277</pub-id>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Porcu</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>O’Buckley</surname>
                      <given-names>TK</given-names>
                    </name>
                    <name>
                      <surname>Alward</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Marx</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Shampine</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Girdler</surname>
                      <given-names>SS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Simultaneous quantification of GABAergic 3α,5α/3α,5β neuroactive steroids in human and rat serum</article-title>
                  <source>Steroids</source>
                  <year>2009</year>
                  <volume>74</volume>
                  <issue>4–5</issue>
                  <fpage>463</fpage>
                  <lpage>473</lpage>
                  <?supplied-pmid 19171160?>
                  <pub-id pub-id-type="pmid">19171160</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sundström-Poromaa</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Comasco</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Sumner</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Luders</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Progesterone–friend or foe?</article-title>
                  <source>Front Neuroendocrinol</source>
                  <year>2020</year>
                  <volume>1</volume>
                  <issue>59</issue>
                  <fpage>100856</fpage>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patterson</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Jepson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Loughead</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Perkins</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Strasser</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Siegel</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Working memory deficits predict short-term smoking resumption following brief abstinence</article-title>
                  <source>Drug Alcohol Depend</source>
                  <year>2010</year>
                  <volume>106</volume>
                  <issue>1</issue>
                  <fpage>61</fpage>
                  <lpage>64</lpage>
                  <?supplied-pmid 19733449?>
                  <pub-id pub-id-type="pmid">19733449</pub-id>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patterson</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Jepson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Strasser</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Loughead</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Perkins</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Gur</surname>
                      <given-names>RC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Varenicline improves mood and cognition during smoking abstinence</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2009</year>
                  <volume>65</volume>
                  <issue>2</issue>
                  <fpage>144</fpage>
                  <lpage>149</lpage>
                  <?supplied-pmid 18842256?>
                  <pub-id pub-id-type="pmid">18842256</pub-id>
                </element-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Heishman</surname>
                      <given-names>SJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Behavioral and cognitive effects of smoking: relationship to nicotine addiction</article-title>
                  <source>Nicotine Tob Res</source>
                  <year>1999</year>
                  <volume>1</volume>
                  <issue>Suppl_2</issue>
                  <fpage>S143</fpage>
                  <lpage>S147</lpage>
                  <?supplied-pmid 11768172?>
                  <pub-id pub-id-type="pmid">11768172</pub-id>
                </element-citation>
              </ref>
              <ref id="CR61">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Heckman</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Dahne</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Germeroth</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Mathew</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Santa Ana</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Saladin</surname>
                      <given-names>ME</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Does cessation fatigue predict smoking-cessation milestones? a longitudinal study of current smokers and recent quitters</article-title>
                  <source>J Consult Clin Psychol</source>
                  <year>2018</year>
                  <volume>86</volume>
                  <issue>11</issue>
                  <fpage>903</fpage>
                  <lpage>914</lpage>
                  <?supplied-pmid 30335423?>
                  <pub-id pub-id-type="pmid">30335423</pub-id>
                </element-citation>
              </ref>
              <ref id="CR62">
                <label>62.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dušková</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Šimůnková</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Hill</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Velíková</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kubátová</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kancheva</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Chronic cigarette smoking alters circulating sex hormones and neuroactive steroids in premenopausal women</article-title>
                  <source>Physiol Res</source>
                  <year>2012</year>
                  <volume>6</volume>
                  <fpage>97</fpage>
                  <lpage>111</lpage>
                </element-citation>
              </ref>
              <ref id="CR63">
                <label>63.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Epperson</surname>
                      <given-names>CN</given-names>
                    </name>
                    <name>
                      <surname>O’Malley</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Czarkowski</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Gueorguieva</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Jatlow</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Sanacora</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy</article-title>
                  <source>Biol Psychiatry</source>
                  <year>2005</year>
                  <volume>57</volume>
                  <issue>1</issue>
                  <fpage>44</fpage>
                  <lpage>48</lpage>
                  <?supplied-pmid 15607299?>
                  <pub-id pub-id-type="pmid">15607299</pub-id>
                </element-citation>
              </ref>
              <ref id="CR64">
                <label>64.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Beattie</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Reguyal</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Porcu</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Daunais</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Grant</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Morrow</surname>
                      <given-names>AL</given-names>
                    </name>
                  </person-group>
                  <article-title>Neuroactive steroid (3α,5α)3-hydroxypregnan-20-one (3α,5α-THP) and pro-inflammatory cytokine MCP-1 levels in hippocampus CA1 are correlated with voluntary ethanol consumption in cynomolgus monkey</article-title>
                  <source>Alcohol Clin Exp Res</source>
                  <year>2018</year>
                  <volume>42</volume>
                  <issue>1</issue>
                  <fpage>12</fpage>
                  <lpage>20</lpage>
                  <?supplied-pmid 29112774?>
                  <pub-id pub-id-type="pmid">29112774</pub-id>
                </element-citation>
              </ref>
              <ref id="CR65">
                <label>65.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Beattie</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Maldonado-Devincci</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Porcu</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>O’Buckley</surname>
                      <given-names>TK</given-names>
                    </name>
                    <name>
                      <surname>Daunais</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Grant</surname>
                      <given-names>KA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Voluntary ethanol consumption reduces GABAergic Neuroactive Steroid (3α,5α)3-hydroxypregnan-20-one (3α,5α-THP) in the amygdala of the cynomolgus monkey</article-title>
                  <source>Addict Biol</source>
                  <year>2017</year>
                  <volume>22</volume>
                  <issue>2</issue>
                  <fpage>318</fpage>
                  <lpage>330</lpage>
                  <?supplied-pmid 26625954?>
                  <pub-id pub-id-type="pmid">26625954</pub-id>
                </element-citation>
              </ref>
              <ref id="CR66">
                <label>66.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stoffel-Wagner</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Neurosteroid metabolism in the human brain</article-title>
                  <source>Eur J Endocrinol</source>
                  <year>2001</year>
                  <volume>145</volume>
                  <fpage>669</fpage>
                  <lpage>679</lpage>
                  <?supplied-pmid 11720889?>
                  <pub-id pub-id-type="pmid">11720889</pub-id>
                </element-citation>
              </ref>
              <ref id="CR67">
                <label>67.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rougé-Pont</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Mayo</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Marinelli</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gingras</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Le Moal</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Piazza</surname>
                      <given-names>PV</given-names>
                    </name>
                  </person-group>
                  <article-title>The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens: Neurosteroids and dopamine release</article-title>
                  <source>Eur J Neurosci</source>
                  <year>2002</year>
                  <volume>16</volume>
                  <issue>1</issue>
                  <fpage>169</fpage>
                  <lpage>173</lpage>
                  <?supplied-pmid 12153544?>
                  <pub-id pub-id-type="pmid">12153544</pub-id>
                </element-citation>
              </ref>
              <ref id="CR68">
                <label>68.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dornellas</surname>
                      <given-names>APS</given-names>
                    </name>
                    <name>
                      <surname>Macedo</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>McFarland</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Gómez-A</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>O’Buckley</surname>
                      <given-names>TK</given-names>
                    </name>
                    <name>
                      <surname>Da Cunha</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Allopregnanolone decreases evoked dopamine release differently in rats by sex and estrous stage</article-title>
                  <source>Front Pharmacol</source>
                  <year>2021</year>
                  <volume>11</volume>
                  <fpage>608887</fpage>
                  <?supplied-pmid 33519475?>
                  <pub-id pub-id-type="pmid">33519475</pub-id>
                </element-citation>
              </ref>
              <ref id="CR69">
                <label>69.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Giatti</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Melcangi</surname>
                      <given-names>RC</given-names>
                    </name>
                    <name>
                      <surname>Pesaresi</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>The other side of progestins: effects in the brain</article-title>
                  <source>J Mol Endocrinol</source>
                  <year>2016</year>
                  <volume>57</volume>
                  <issue>2</issue>
                  <fpage>R109</fpage>
                  <lpage>R126</lpage>
                  <?supplied-pmid 27339142?>
                  <pub-id pub-id-type="pmid">27339142</pub-id>
                </element-citation>
              </ref>
              <ref id="CR70">
                <label>70.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stanczyk</surname>
                      <given-names>FZ</given-names>
                    </name>
                  </person-group>
                  <article-title>All progestins are not created equal</article-title>
                  <source>Steroids</source>
                  <year>2003</year>
                  <volume>68</volume>
                  <issue>10</issue>
                  <fpage>879</fpage>
                  <lpage>890</lpage>
                  <?supplied-pmid 14667980?>
                  <pub-id pub-id-type="pmid">14667980</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
